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ABSTRACT 
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CAPSULE, O-ANTIGEN, PATHOGENESIS AND GENOME 
 
 Yuansha Chen, Ph. D., 2006 
Directed by Professor J. Glenn Morris, Program in Marine Estuarine Environmental 
Sciences 
 
Vibrio cholerae is the causative agent of cholera.  In order to understand the 
genetic basis underlying the emergence of novel epidemic strains of V. cholerae, the 
genetics of surface polysaccharide biogenesis, and the role of lateral gene transfer in the 
evolution of this species, we investigated. 
NRT36S and A5 are both NAG-ST producing, cholera toxin negative, serogroup 
O31 V. cholerae.  NRT36S is encapsulated and causes diarrhea when administered to 
volunteers; A5 is acapsular and does not colonize or cause illness in humans.  The 
structure of the capsular (CPS) polysaccharide in NRT36S was determined by NMR.  
The gene cluster of CPS biogenesis was identified by transposon mutagenesis combined 
with whole genome sequencing data.  The CPS gene cluster shared the same genetic 
locus as that of the O-antigen of lipopolysaccharide (LPS) biogenesis gene cluster.  The 
LPS biogenesis regions in A5 were similar to NRT36S except that a 6.5 kb fragment in 
A5 replaced a 10 kb fragment in NRT36S in the middle of the LPS gene cluster.   
The genome of NRT36S was sequenced to a draft containing 174 contigs plus the 
superintegron region.  Besides confirming the existence of NAG-ST, we also identified 
 
the genes for a type three secretion system (TTSS), a putative exotoxin, and two different 
RTX genes.  Four pili systems were also identified.  Therefore, the genome of non-O1 
Vibrio cholerae NRT36S demonstrates the presence of pathogenic mechanisms that are 
distinct from O1 V. cholerae.  
We conclude that lateral gene transfer plays a critical role in the emergence of 
new strains.  The co-location of CPS and LPS could provide a mechanism for 
simultaneous emergence of new O and K antigens in a single strain.  Our data also 
highlights the apparent mobility within the CPS/LPS region that would provide a basis 
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PREFACE 
My dissertation contains the full text of three manuscripts that will be published in 
scientific journals. 
Chapter II contains the full text of the manuscript entitled “The capsule biogenesis 
genes are embedded in the LPS region in non-O1 Vibrio cholerae NRT36S”, returned for 
revision, 2006.  I wrote the first draft of the manuscript and circulated it to my co-
authors.  I incorporated their revisions through 12 drafts.  I performed the transposon 
mutagenesis with the Km-2 transposon and advice from Afsar Ali.  I picked and grew the 
mutants and stored them in -80ºC.  I extracted genomic DNA from the translucent 
mutants.  I mapped the position of the transposons in the mutants.  I performed all of the 
sequencing and the subsequent analyses of the excised clones including reading, 
assembly and annotation.  I combined data from 454 with my own data and filled gaps in 
the capsule/LPS region by designing primers, PCR amplifying and sequencing the 
products.  Again, I performed the assembly, and annotation and comparison of the 
sequences to GenBank.  I performed the serum killing assays under the direction of 
Judith Johnson.  I conceived of the HPLC analysis and directed its completion by the 
Biopolymers Core.  I performed the gel electrophoresis and immunoblotting.  I prepared 
samples for the EM experiments and gave them to Pinaki Panigrahi for embedding and 
sectioning.  Pinaki and I then looked at the samples together under EM and took pictures.  
I cloned galE gene and performed the complementation experiment.  Peter Bystricky, 
Jacob Adeyeye and Allen Bush conducted the work towards resolving the capsule 
structure of V. cholerae NRT36S.   
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Chapter III contains the full text of the manuscript entitled “The genome of non-O1 
Vibrio cholerae NRT36S demonstrates the presence of pathogenic mechanisms that are 
distinct from O1 Vibrio cholerae”, returned for revision, 2006.  I grew the bacteria and 
isolated the DNA.  The genome was sequenced by the company 454 Life Science.  It was 
automatically annotated by Gordon D. Pusch in the National Microbial Pathogen Data 
Resource.  I compared the genomes, assembled the differences and performed further 
manual annotation.  I compared the genomes with the program MUMMER; edited the 
results with Microsoft Excel and analyzed the difference.  I compared the proteomes of 
the two strains with a stand alone Blast program.  When using these programs, I built up 
the local databases.  I wrote the first draft of the manuscript and incorporated edits and 
revisions from my co-authors through 10 drafts. 
Chapter IV contains the full text of the manuscript “Genetic variation of 
capsule/lipopolysaccharide biogenesis in two serogroup O31 Vibrio cholerae isolates”, in 
preparation, 2006.  I conceived of the idea to compare the CPS/LPS region of these 
genomes.  I developed primers and amplified across the region to find the differences.  I 
sequenced, assembled and confirmed the assembly for the disparate region.  I manually 
annotate the LPS region in NRT36S and A5.  I retrieved data from GenBank for the 
phylogenetic trees.  I analyzed the GC content in the CPS/LPS regions.  I wrote the first 
draft of the manuscript and incorporated suggestions and comments from my co-authors 
J. Glenn Morris, Jr., O. Colin Stine and Judith A. Johnson. 
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CHAPTER I: INTRODUCTION AND BACKGROUND 
VIBRIO CHOLERAE 
Microbiology and Ecology 
Vibrio cholerae is the causative agent of the devastating epidemic disease cholera.  
It is a motile, curved gram-negative rod; capable of both respiratory and fermentative 
metabolism.  There are several biochemical features that can distinguish V. cholerae from 
the Enterobacteriacean.  It is oxidase positive; it can grow in nutrient broth with added 
NaCl; it does not produce gas from glucose, and it ferments sucrose to give a yellow 
colony on TCBS agar.  V. cholerae is a heterogeneous species.  Some serogroups cause 
epidemics of the disease cholera, others are responsible for intestinal infections in small 
outbreaks or in an individual; some cause extraintestinal infections, and the rest are 
considered harmless environmental isolates.   
The natural habitat for V. cholerae is an estuarine environment, but it can persist in 
both marine and fresh water.  It can exist in free living form, associated with 
phytoplankton and zooplankton, in biofilms, and even in a so call “viable but non-
culturable (VBNC)” form.  V. cholerae can be readily isolated from the natural coastal 
water.  The ecology of it is not fully understood.  But studies conducted by Colwell’s 
group in Chesapeake Bay, Maryland identified several environment parameters that 
affect the distribution V. cholerae in its natural reservoir (1-3).  The two parameters affect 
the distribution of V. cholerae the most are temperature and salinity.  When water 
temperatures were warmer than 19°C and the salinity was between 2-8 ppt, about 80% of 
the samples collected were positive for V. cholerae (3).  Only non-O1 V. cholerae was 
cultured from these environmental samples.  O1 V. cholerae was not isolated by 
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traditional culture method but was detected in about the same frequency, only when a 
direct fluorescent-antibody assay was used.  That suggests O1 V. cholerae may exist in 
nature in a VBNC state.  VBNC is a survival strategy for bacteria when they encounter 
stress conditions (4).  Bacteria are dormant in this state.  They become smaller in size; 
their metabolism is very slow; and they significantly reduce their macromolecules 
including lipid, carbohydrate, proteins and DNA.   
Colwell et al’s findings are consistent with the results of investigating the 
distribution of toxigenic (O1 and O139) V. cholerae in the aquatic environment around 
the cholera endemic area.  In India and southern Bangladesh, cholera erupts seasonally, 
twice a year, once before, and once after the monsoon season (5).  Toxigenic V. cholerae 
are rarely isolated by culture from coastal waters in these areas in between the outbreaks, 
and they are cultured only infrequently even during epidemic period (6).  In the contrast, 
non-O1, non-O139 V. cholerae are isolated in culture from almost every sample collected 
from the same area (7).  But using fluorescent monoclonal antibody against O1 
serogroup, toxigenic O1 could be detected in the aquatic environment in the cholera 
epidemic area (6).  Now, it is known that toxigenic V. cholerae exist as a VBNC form 
and was not picked up by traditional laboratory culture method (8).  VBNC V. cholerae 
O1 recovers in fully virulence when inoculated into rabbit intestine (9).   
An important survival mechanism for V. cholerae is to live in biofilms.  A recent 
study by Alam et al. (7) surveyed the bay of Bengal for V. cholerae, using a combination 
of methods including direct fluorescent antibody count and fluorescent microscope.  They 
found a large number of O1 V. cholerae in thin films of exopolysaccharides (biofilm).  In 
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biofilms the cells are clumped and their shapes do not show the typical curved rod of the 
free living form.  Survival is better in biofilms compared to free living (10-12).   
Matz et al. found that embedding in biofilms was a strategy for V. cholerae to avoid 
protozoan grazing (13).  In their study, they compared the amount of planktonic versus 
biofilm embedded V. cholerae grazed by protozoa and they found the planktonic V. 
cholera was quickly grazed by protozoa.  But V. cholerae embedded in biofilm was 
protected from protozoan grazing.  Matz et al. also found that there were two protecting 
factors:  i) Biofilms provide a physical barrier for the grazers.  ii) V. cholerae embedded 
in biofilms secretes a factor, under the control of quorum sensing, that is against 
protozoan predation.  The nature of the factor secreted is yet to be investigated. 
The current serotyping scheme of V. cholerae is based on the O-antigen of the 
lipopolysaccharide (LPS) with more than 200 serogroups reported (14).  Only serogroups 
O1 and O139 of V. cholerae cause epidemic cholera and frequently carry cholera toxin.  
Because of the severe symptoms and high mortality of cholera, and also because its great 
tendency to spread and cause world-wild explosive outbreaks, the disease cholera and 
serogroup O1 and O139 V. cholerae have been studied extensively.  There have been 7 
pandemics of cholera recorded, with the fifth and sixth pandemics caused by O1 classical 
and the seventh pandemic caused by O1 El Tor, and the previous ones are believed also 
to be caused by O1.  Besides these seven pandemics, there may be also an 8th pandemic 
of cholera beginning, which started in the 1990’s in India and Bangladesh; caused by a 
new serogroup O139, designated as O139 Bengal.  O139 Bengal is very similar to O1 El 
Tor genetically except for the region encoding its surface polysaccharides (15-17).  Other 
serogroups, including O37 Sudan, have sometimes caused cholera like disease in small 
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outbreaks.  O37 Sudan was found to have arisen from O1 classical by switching its O-
antigen (18).  O1 and O139 frequently carry cholera toxin. Thus O1 and O139 are also 
referred to as toxigenic V. cholerae.  Occasional non-toxigenic O1 isolates are found in 
the environment.  O1 isolates can be further subdivided into serogroups Inaba and Ogawa 
and biotypes classical and El Tor. 
Most of non-O1, non-O139 V. cholerae in the environment do not carry cholera 
toxin genes, but may carry other toxins and be harmful if ingested.  An earlier survey to 
the Chesapeake Bay in Maryland isolated 65 isolates of non-O1 V. cholerae.  About 87% 
of them displayed toxicity for Y-1 adrenal cells and majority of them were positive for 
fluid accumulation in ileal loops experiments, suggesting the presence of enterotoxins.  
Non-O1, non-O139 V. cholerae do occasionally cause diarrhea, and sometimes are also 
isolated from extraintestinal infections including blood, wounds, ear, and other sites (19). 
Genetic Backbone 
The genome of V. cholerae isolate N16961, serogroup O1, biotype El Tor, has been 
sequenced (20).  The genome is 4,033,460 base pairs (bp).  There are two chromosomes 
in V. cholerae with a total of 3885 genes identified.  Most of the genes are similar to 
Escherichia coli genes, but 12.8% of the genes show highest similarity to the other V. 
cholerae genes and suggest recent duplication.  Chromosome I harbors most of the genes 
essential for cell functions such as metabolism and pathogenesis.  Genes encoding the O1 
specific LPS are also on chromosome I.  On chromosome II, the genes are mostly 
hypothetical proteins with unidentified functions.  Because of the presence of many 
plasmid origin genes (20), chromosome II was suggested to be derived from a 
megaplasmid that was captured by an ancestral Vibrio species.  Chromosome II harbors a 
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large integron (superintegron) which is about 125 kb and encodes 215 open reading 
frames, each one flanked by a V. cholerae repeat.   
The genomes of Vibrio vulnificus and Vibrio parahaemolyticus were also 
sequenced (21, 22).  Both of these two species also have two chromosomes.  
Chromosomes I in both V. vulnificus and V. parahaemolyticus have similar sizes to 
Chromosome I in V. cholerae.  Chromosomes II in V. vulnificus and V. parahaemolyticus 
have similar sizes (1.9 mb), but they are bigger than the size of chromosome II in V. 
cholerae (1.0 mb).  Comparative genomic analysis showed that V. vulnificus and V. 
parahaemolyticus have a higher degree of conservation in gene organization.  V. cholerae 
has extensive genome rearrangement compared to V. vulnificus and V. parahaemolyticus 
(21, 22).  Makino et al. compared genes between V. cholerae and V. parahaemolyticus 
(21, 22).  There is 16.2% and 29.5% of genes specific to V. parahaemolyticus and V. 
cholerae respectively in the chromosome I.  There is 41.9% and 56.8% of genes specific 
to V. cholerae and V. parahaemolyticus respectively in Chromosome II.   
House-keeping genes, conserved in the genome, are used as indicators of the 
genetic relationship among different isolates of V. cholerae.  Two techniques, multi locus 
sequencing typing (MLST) and multi locus enzyme electrophoresis (MLEE), have found 
V. cholerae to be a genetically diverse species (23-25).  In contrast, the epidemic strains 
were found to be closely related, forming a tight clonal cluster in the phylogenetic tree, 
separate from the environmental isolates.  Using MLEE, Beltran et al. studied the 
polymorphism of 17 enzymes in an extensive collection of 397 V. cholerae isolates, 
including the O1 classical, O1 El Tor pandemic strains, O139 epidemic strains, and 
environmental strains (23).  They found most of the O1 epidemic strains and all O139 
 5
epidemic strains have the identical electrophoretic types (ETs), while some O1 epidemic 
strains differ to this ET in only one enzyme locus.  The O37 isolates from Sudan 
epidemic also differed from the main pandemic ETs at a single locus.  The environmental 
stains included in this study are diverse and form many clusters, separating from the 
epidemic clusters.  This result was consistent with the findings by Wachsmuth’s group at 
the CDC (26).  It is also consistent with the finding from other groups that O139 may 
have arisen from an O1 El Tor strain by acquiring new LPS biogenesis region (15, 17, 
27).   
Sequence typing has been used to determine the genetic relationship among the V. 
cholerae isolates from the 6th, 7th pandemics and the US Gulf coast.  Reeves et al. 
initially studied the polymorphism of one housekeeping gene asd and concluded that the 
6th, 7th pandemic and US Gulf isolates arose from different clones (28).  Later on, the 
same group, by studying 4 more housekeeping genes, concluded that the epidemic clones 
are actually very closely related (24). 
There were also studies looking at the diversity among the O139 epidemic isolates.  
Farfan et al. looked at the six house-keeping genes in the O139 Bengal isolates and found 
the 29 isolates fall into three different groups and therefore concluded that they may 
derive from different ancestral clones (29).  But since they did not include many isolates 
of the other serotypes or from other sources as reference, the variation among those O139 
Bengal isolates may just represent the variation after the O139 epidemic strain arose and 
their conclusion that the origin is polyclonal is questionable.  Garg et al. analyzed nine 
housekeeping loci in the 96 V. cholerae O139 isolates from the same hospital and 
identified 51 different sequence types (25).  In summary, the genetic backbones in all the 
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epidemic strains are very similar, and may have separated from the environmental strains 
long time ago. 
Virulence Factors 
The pathogenesis mechanism in the pandemic V. cholerae has been investigated 
extensively.  The major virulence factors are cholera toxin (CT) and toxin co-regulated 
pilus (TCP) (30-34).  CT is encoded in the genome of a filamentous phage CTX∅, 
incorporated into the chromosome I of V. cholerae (32).  CT consists of five B subunits 
and one A subunit (35, 36).  During infection, B subunits bind to the GM1 ganglioside 
receptors in the host small intestinal mucosa; subunit A then travels into cells, increases 
the level of cAMP via G-protein, and subsequently interferes with the function of ion 
channel for Cl-.  This leads to net water flux into the lumen of the human intestine and 
causes diarrhea (37-39).   
TCP is a type IV pilus and the major colonization factor for V. cholerae.  It is also 
the receptor for CTX∅.  Some strains only have TCP but lack CTX∅ (40).  TCP is 
encoded in a 39.5 kb region of the V. cholerae genome, designated VPI-1 (30).  All the 
strains that demonstrated the ability to cause epidemic cholera are positive for both CT 
and TCP.  Besides CT and TCP, other toxins have been reported, including Ace, Zot, 
RTX, etc. (19). 
The impact of non-O1 and non-O139 V. cholerae may have been overlooked.  
During cholera epidemics period, they are isolated from up to 13% of patients with 
cholera-like disease (41).  In contrast to the epidemic strains, pathogenesis by non-O1, 
non-O139 V. cholerae is not well understood.  There are different toxins reported and 
sometimes results are controversial from studies conducted with different isolates.  In an 
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animal model study and a volunteer study, a heat stable enterotoxin (NAG-ST) was found 
to be a critical virulence factor to cause diarrhea by an O31 strain NRT36S (41).  But 
NAG-ST along is not enough to cause disease since a similar O31 strain A5, also NAG-
ST positive, is not pathogenic.  The colonization factor that possibly made the difference 
in terms of pathogenesis between NRT36S and A5 was not identified. 
SURFACE POLYSACCHARIDE 
General Classification 
Like other gram-negative bacteria, the surface of V. cholerae is coated with 
complex polysaccharides.  Three major surface polysaccharides exist: lipopolysaccharide 
(LPS), which is covalently bound to the cell outer membrane by a lipid A anchor; a 
capsule, which normally has higher molecular weight and exists as moiety closely 
associated with the cell; and an exopolysaccharide, which is a loose slime outside the cell 
that forms an intercellular matrix in biofilms.  Exopolysaccharide are expressed in the 
cells that display a rugose (wrinkle) phenotype.  Rugose is discussed in the section of 
“phase variation”.  This exopolysaccharide is not with the scope of this study.   
LPS is attached to the outer membrane in gram-negative bacteria and is also referred 
to as endotoxin.  In epidemic V. cholerae O1, it is the outer most layer of the cell and has 
direct contact to the host environment.  LPS was shown to adhere to the intestinal mucosa 
and may contribute to colonization during infection (42, 43).  Infection with V. cholerae 
can result in protective immunity against re-infection with the same serogroup (44, 45).  
The protective immunity comes from both anti-bacterial and antitoxin responses with the 
most important immunity being the antibacterial immunity.  The antibacterial antibodies 
are mostly absorbed by the LPS, strongly suggesting that the protective immunity mostly 
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comes from LPS (38).  The current most effective vaccine is a combination of killed 
whole bacterial cells and purified toxin subunit B, to activate both vibriocidal and 
antitoxin antibodies. 
LPS consists of three parts including lipid A, core and O side chain.  The highly 
antigenic O side chain is often referred to as O antigen.  The lipid A and core are 
conserved, while the O antigens are highly variable.  The genetic location of the O 
antigen biogenesis gene clusters is conserved at a specific site of the genome in V. 
cholerae.  O-antigen regions for 7 serogroups of V. cholerae have been identified and 
sequenced and they are all between the two genes gmhD and rjg (46-49).  Examination of 
the gene clusters in different serogroups of V. cholerae found that the genetic 
composition between these flanking genes is highly variable.  For example, the O antigen 
region in serogroup O1 has been replaced by an entirely different fragment in O139 and 
O37 and there is very little common sequence in this region shared by the three 
serogroups.  Thus the epidemic strains have changed their O-antigens while maintaining 
their toxic genetic backbone, as we see from the rise of V. cholerae O139 Bengal and 
O37 Sudan from O1 progenitors.  This potential for change probably extends to non-
toxigenic strains as well.  Sequence from O antigen gene clusters from 4 additional 
serogroups, O5, O8, O37, O108, by Aydanian et al., (46) found no conserved 
organizational motif, and only a very few genes shared by these 4 different clusters (46).  
In contrast, the O139 O antigen region is found to be very similar to O22.  The 
organization and the content of the genes for O antigen biogenesis are highly conserved 
between these two serogroups with a small divergent region associated with an insertion 
sequence (49). 
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The second major surface antigen, the capsule, is composed of high molecular 
weight polysaccharide and forms a dense thick coat outside of the bacterial cells.  How 
the capsule attaches to the cell membrane is not well understood.  The capsule helps the 
bacteria to escape the host immune system by masking the LPS and hence avoid 
triggering the non-specific defense system.  The capsule also protects the bacteria from 
complement-mediated phagocytosis and complement-mediated killing.  Therefore 
capsule is a virulence factor itself; its virulence role is essential for pathogenesis in non-
O1 V. cholerae (50) and some pathogenic bacteria like Streptococcus pneumoniae (51) 
and V. vulnificus (52, 53).  Encapsulated pathogens can become invasive and cause 
septicemia due to increased resistance to complement-mediated killing.  The capsule is a 
critical virulence factor in extraintestinal infections caused by V. vulnificus and non-O1 
V. cholerae (41, 50, 54, 55).  A case report of V. cholerae O139 that caused septicemia in 
immuno-compromised patient raises concerns for vaccine development with encapsulated 
V. cholerae such as O130 strains (17, 56). 
Capsule Biogenesis 
Capsule biogenesis has been studied in many species including E. coli, Salmonella 
typhi, Neisseria meningitides, Haemophilus influenzae, Klebsiella pneumoniae and 
Streptococcus pneumoniae.  Among them, capsules in E. coli are studied most 
extensively and serve as model systems for the other species.  Capsule biogenesis in the 
other species is more or less similar to E. coli.  The capsule types in E. coli display 
striking diversities.  E. coli has more than 80 capsule types and they are classified into 4 
groups according to a scheme proposed by Whitfield’s group (57).  This classification 
scheme considers both the thermo-stability and genetic properties.   
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Groups 1 and group 4 capsules are thermo stable and share many common features 
genetically.  In group 1 and group 4, a proportion of the K (capsule) antigen is attached to 
the oligosaccharide core and is termed Klps, while the rest of the K-antigen is not attached 
and forms a capsule (58).  In most cases, there is also an additional O-antigen attached to 
the same core in these two groups.  Occasionally, there is no other O-antigen except the 
Klps present in E. coli that express group 4 capsules.  The capsule gene clusters for groups 
1 and 4 reside in a region define where the O antigen cluster resides for groups 2 and 3 of 
E. coli.  It maps closely to the his operon at 45 min in the genome.  Group 4 capsules can 
co-express with colanic acid while group 1 capsules do not.  Colanic acid is an 
exopolysaccharide expressed by many E. coli (59).  The biosynthesis gene cluster of 
colonic acid is close to the his operon; it is lost and replaced by the group 1 capsule gene 
cluster in some E. coli.  Besides genes at the 45 min locus, there are other genes related to 
the groups 1 and 4 capsule synthesis at the 22 min position.  Genes in the 22 min locus 
are redundant for group 1 capsule biogenesis, but they are necessary for the group 4 
capsule biogenesis. 
Groups 2 and 3 capsules are thermo-labile.  Their gene clusters in E. coli occupy the 
same location near the ser operon in the genome mapped to 68 min.  The capsule clusters 
in these two groups are very similar in terms of their organization; both consist of 3 
regions, with the two conserved regions flanking the serogroup specific region.  The 
genes in the two conserved regions are responsible for the polysaccharide process and 
exportation.  In the serogroup specific region, the gene content is very different in group 
2 and group 3 (60).  First the genes of the serogroup specific region encode enzymes that 
synthesize different sugar subunits and repeating units.  Second, groups 2 and 3 capsules 
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also differ in their thermo regulatory properties.  Group 2 capsules are not expressed in 
low temperatures below 20°C (61, 62).  Group 3 capsules are express under all growth 
conditions. 
There are limited strategies employed by the bacteria to synthesize polysaccharides.  
The biosynthesis pathways are found to be conserved.  Whitfield et al. gave several 
excellent reviews on the capsule biogenesis in E. coli (57, 63, 64).  Although there are 
extensive studies on the capsule biogenesis pathways, a lot still remain unknown or 
unclear, partly because the capsule biosynthesis is a complicated suite of the functions of 
multiple proteins with complex interactions.   
Capsules can consist of either a homopolymer or a heteropolymer.  The synthesis 
pathways then differ by the nature of the polymer.  The sugars constitute the repeating 
unit and the polysaccharides are linked and polymerized.  The capsule then needs to be 
exported across the cell envelop, and to the cell surface.   
Capsules in groups 1 and 4 consist of heteropolymers.  Individual sugars are added 
to a lipid carrier in the cytoplasm membrane to compose an oligo sugar subunit, by 
specific glycosyltransferases.  The repeating oligo sugar units are then translocated to the 
periplasmic by a translocase wzx, and are polymerized by a polymerase wzy.  The 
exportation of capsule polymer involves gene products of wza, wzb and wzc.  The current 
model favors the forming of a multiple protein complex spanning the entire cell envelop.  
The requirement for wza, wzb and wzc is a common character shared by groups 1 and 4 
capsules and differentiates them from groups 2 and 3 capsule.  In group 1, wza, wzb and 
wzc are located together with the rest of the capsule genes near the his operon.  But in 
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group 4, wza, wzb and wzc are at the 22min locus, separated from the rest of the capsule 
genes. 
Groups 2 and 3 capsules in E. coli employ a different synthesis strategy to groups 1 
and 4.  Wzx and wzy genes are absent from groups 2 and 3 capsule gene clusters.  Instead, 
groups 2 and 3 depend on an ABC transporter system to carry the polymerized 
polysaccharide across the inner membrane.  Chain elongation in these two groups of 
capsule is possibly processive by the glycosyltransferase activity in the cytoplasmic site 
of the inner membrane (57).  The polymer is then transported to the periplasmic area by 
the ABC transporter.  The ABC transporter consists of two proteins, Wzm and Wzt.  
Wzm is a membrane protein while Wzt is an ATPase.  The capsule polysaccharide is then 
exported to the outer surface of the bacteria.  The current model suggests this last step 
depends on the function of two additional gene products, kspE and kspD.  
Capsules have been studied in other pathogenic bacteria too.  There have been more 
than 90 capsule types identified for S. pneumoniae (65).  Capsule is an essential virulence 
factor in S. pneumoniae.  The classical experiments in the study of its virulence 
ultimately lead to the discovery that genetic material is DNA (51).  The genetic loci of all 
90 capsule types of S. pneumoniae had been identified and sequenced (66, 67).  With one 
exception, all loci are in the same location of the genome, between genes dexB and aliA.  
The organization of the capsule clusters in S. pneumonia is similar to the group 2 capsule 
in E. coli, with conserved regions flanking the serogroup specific region.  The exception 
in S. pneumonia is type 37.  The genes to synthesize type 37 capsule is located far away 
from dexB and aliA.  But interestingly, there is a silent copy of capsule gene cluster 
between dexB an aliA for pneumococci that expresses type 37 capsule. 
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Capsule gene clusters in both Haemophilus influenzae type b and Neisseria 
meningitidis group B are organized remarkably similar to group 2 capsules in E. coli.  
But something very unique is found in N. meningitidis.  The capsule biogenesis region is 
organized in 5 sectors in group B N. meningitides (68) (69, 70).  Similar to group 2 E. 
coli, the polysaccharide processing and transportation genes are conserved and flanking 
the capsule type specific genes.  The two regions in the middle, regions A and D are type 
specific.  Interestingly, region D is related to lipooligosaccharide synthesis and mutations 
in this region result in a truncated lipooligosaccharide. 
Capsules of Vibrio Species 
There are limited studies on the capsule biogenesis in the genus Vibrio.  Capsules 
are important virulence factors in V. vulnificus, V. parahaemolyticus and non-O1 V. 
cholerae.  There are many capsule types in V. vulnificus.  Wright et al. identified a 
genetic locus for capsule biogenesis in V. vulnificus M06-24 (71).  The presence of wza 
gene in this locus suggests it is similar to group 1 capsule in E. coli.  Smith el at also 
identified a capsule gene cluster in V. vulnificus 1003 (72).  The capsule genes in 1003 
include a wzx and a wzy, suggesting it is also a group 1 capsule.  In both of these cases, 
the capsule gene clusters are not complete and the understandings to capsule biogenesis 
in V. vulnificus are impaired. 
More than 85% of non-O1 Vibrio cholerae isolates have a capsule (73).  The 
capsule is a critical virulence factor in extraintestinal infections.  Johnson et al. found that 
the loss of capsule in a naturally encapsulated pathogenic strain V. cholerae NRT36S 
confers less virulence in mouse models (50).  However, the pandemic strain that most 
associated with cholera, serogroup O1, lacks a capsule and only has an LPS.  This raises 
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an interesting question whether the loss of function for the capsule increases virulence in 
diarrhea disease. 
The newly emerged epidemic strain V. cholerae O139 has a capsule.  But O139 
capsule is an O-antigen capsule, in which the O-antigen and the capsule share the same 
repeating unit.  One repeating unit attaches to the LPS core and behaves as an O-antigen, 
the same repeating units also polymerizes but does not seem to attach to the core, and 
hence behaves as a capsule (74-76).  Genetically, the gene cluster for capsule 
polysaccharide biogenesis in O139 replaces the gene clusters for the O-antigen gene 
cluster in O1 and resides in the same position on the genome, between the genes gmhD 
and rjg (49).  Therefore, the same polysaccharide in V. cholerae O139 represents both 
capsule and O-antigen and resembles the group 4 E. coli capsule (64), yet is different 
from the most of the group 4 capsule because V. cholerae O139 does not have another O-
antigen attached to the core. 
In V. cholerae the atypical capsule of O139 is the only well studied capsule, other 
capsules and their biogenesis are essentially unknown.  However, since the majority of 
the isolates of V. cholerae have capsules, the elucidation of capsule biogenesis in this 
species is a critical part of understanding the evolution of the surface polysaccharides, to 
understanding the internal relationship between the capsule and LPS, and furthermore to 
understanding the genetic basis underlying the emergence of novel epidemic strains.  As 
indicated from the other species, surface polysaccharide evolves in a similar and module-
like pattern as pathogenicity islands.  Whether this is true in the highly diverse species of 
Vibrio cholerae needs to be answered.   
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PHASE VARIATION 
Types of phase variation 
Phase variation in bacteria refers to bacteria switching between two phenotypes, 
usually differences in colony morphology, and that switching is inheritable and 
reversible.  Bacteria can switch between opaque and translucent, rough and smooth, or 
dry and moist.  These morphology changes generally reflect the structural changes on the 
bacterial surface, including polysaccharide, pilus, outer membrane protein, or cell wall 
composition.  Although the frequency of phase variation varies, it is higher than the 
frequency of point mutation.  Phase variation is especially well recognized in pathogenic 
bacteria and is often associated with changes in virulence.  The reason bacteria undergo 
phase variation is not clear.  It may be a survival strategy for bacteria, perhaps to avoid 
host immune system, to alter attachment, and sometimes for improved interaction 
between bacteria to the environment.   
Phase variation occurs when expression level changes in one or more proteins due 
to controlled modification of their DNA.  It can be associated with changes in the 
expression of exopolysaccharide, capsule, LPS, outer membrane proteins, or granules in 
the cells.  The changes could be absence or presence, higher or lower levels of 
expression, or structural changes. 
The production of an exopolysaccharide can cause phase variation in bacteria.  
Colonies of Vibrio sp. can display rugose (wrinkle) or smooth phenotype (68).  Both 
rugose and smooth variants of V. cholerae are virulent.  Rugose phenotype is caused by 
an exopolysaccharide excreted by the cell.  This exopolysaccharide forms slime and 
causes cells to clump together.  As a result, colonies have a wrinkled surface and are 
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more resistant to biocides.  Genes for exopolysaccharide production have been identified 
in V. cholerae (77-79).  They are very similar to the exopolysaccharide genes in V. 
parahaemolyticus.  These genes are under the control of opaR (80).  Exopolysaccharide 
is important in biofilm formation.  Under stressful conditions such as protozoan grazing, 
V. cholerae may switch to the rugose phenotype (13).   
The status of encapsulation in bacteria also affects their colony morphology.  
Colonies are more opaque when encapsulated and translucent when not.  Encapsulated 
non-O1 V. cholerae can spontaneously switch from opaque to translucent and reversibly 
switch back (50) and the opacity is correlated to the capsule amount when examined by 
electron microscope or by the combination of a stereoscope and transmitted oblique 
illumination technique (13).  The similar kind of phase variation happens in V. vulnificus 
and V. parahaemolyticus (71, 72) (81).  Phase variations due to the capsulation statues 
are also reported from many other bacteria including Neisseria meningitides (82, 83) and 
Streptococcus pneumonia (84).   
Phase variation may result from the alteration in third surface polysaccharide, LPS.  
Although LPS is a structural part of the cell membrane in gram negative bacteria and 
bacteria lacking the entire structure are not viable, there are rough or semi rough strains 
of bacteria that only express the lipid A and core of the LPS and do not express or only 
express a very short O-side chain.  The modifications in bacteria LPS side chain length 
affect their sensitivity to serum killing.  Lipooligosaccharide (LOS) in Campylobacter 
jejuni mimics human ganglioside (GM) and causes Guillain-Barré syndrome.  Linton et 
al. reported C. jejuni can expressed GM1 or GM2 like LOS and the two types of LOS are 
phase variants (85). 
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Fourth common cause of phase variation is because of the differential expression of 
proteinaceous structures on the cell surface.  That includes various types of pilus and 
flagella.  Pili act as adhesins for bacteria to interact with the environment or act as 
bridges between different cells.  E. coli phase varies its type 1 pili (86).  S. enterica 
encodes at least 11 pili, 4 of them were found to undergo phase variation (87).  N. 
gonorrhoeae phase vary its pili.  There are multiple pilus subunit genes in the genome 
and only one is expressed at a time.  N. gonorrhoeae can phase vary a large number of 
distinct pili (88).  Flagellum is another proteinaceous structure on bacteria cell surface.  It 
can function for bacteria motility and adhesion.  Flagella can undergo phase variation in 
C. jejuni and H. pylori (89, 90).  As a result, motilities are affected in those bacteria 
undergo flagella phase variation. 
The opacity change in colony morphology can also be caused by the phase variation 
of outer membrane proteins.  N. gonorrhoeae can not only phase vary its pili, but a subset 
of surface proteins, known as opacity proteins (opa).  There are multiple copies of opa in 
each N. gonorrhoeae strain and each opa gene phase varies (91, 92).  Each opa gene 
contains two hyper-variable regions.  Each gene can switch between on and off 
expression state, and can also change the content in its hyper-variable region.  Therefore, 
the potential of N. gonorrhoeae to undergo phase variation is enormous.  The S-layer 
protein in Campylobacter fetus is another example to go extensive phase variation.  S-
layer proteins form a thick matrix outside the cell of C. fetus and completely cover the 
LPS and hence protect the cell from antibody mediated opsonization.  There are 6-9 
copies of S-layer protein genes in the genome, clustering closely together.  Only one gene 
is expressed in a cell.  Recombination between different S-layer protein gene copies can 
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alter the protein expressed (93).  Another membrane protein was found to associate with 
colony opacity in V. cholerae too.  A 27 kDa outer membrane protein was found present 
in the translucent variant but absent from the more opaque variants of both O139 and O1 
serogroups (13). 
Another fifth factor reported to affect colony opacity and it is not on the cell 
surface.  Poly-β-hydroxybutyrate forms granules in the cell and the amount of it present 
is positively correlated with the colony opacity in V. cholerae (13). 
Molecular Mechanisms of Phase Variation 
Bacteria employ different molecular mechanisms to produce phase variation.  The 
most common theme identified is slipped-strand mispairing (SSM).  This mechanism 
involves DNA sequence consisting of tandem repeats that have 1 to 7 nucleotides in the 
repeating unit.  During DNA replication, mispairing can happen between mother strand 
and daughter strand of DNA, give rise to a reduced or increased number of tandem repeat 
in daughter DNA.  If SSM happens in the promoter region, transcription can be turned on 
or off depends on the number of repeats.  If SSM happens in the coding region, it could 
introduce a premature stop codon, the reading frame is shifted.  In H. influenzae, the 
genes hif encodes fimbriae.  There is a dinucleotide TA repeats in the promoter of hif 
genes, between the -10 and -35 positions.  The repeat numbers varies from 9, 10 or 11.  
The expression level of hif genes change, depends on the number of repeats present (94).  
Phase variation by SSM mechanism has also been identified in other species including H. 
pylori (95), N. gonorrhoeae (96), N. meningitides (97), Bordetella pertussis (98) etc.  
Homologous recombination is another common mechanism for phase variation.  
Genes that associated with this molecular mechanism of phase variation have multiple 
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copies, but only one copy is active and the others of them are silent because of the 
absence of promoters.  When gene in the expression site recombines with a silent gene in 
the repertoire, it results in the expression of a different protein.  This mechanism is well 
illustrated in the phase variation of N. gonorrhoeae pilin proteins (99, 100).  The pilin 
proteins of a type IV pilus in N. gonorrhoeae are conserved for two thirds of the N 
terminal and vary at the C terminal.  The pilin proteins are encoded by pil genes.  There 
are several loci of the pil genes in the genome but only one locus is the expression site 
and termed pilE.  The other loci are silent and termed pilS.  PilS locus consist most of the 
variable genes.  During DNA replication, genes in the pilE locus can recombined with 
genes in the pilS loci and express different pilus structure.  S-layer proteins in C. fetus 
also phase varies under a similar mechanism (93).   
There are other two mechanisms of phase variation that are based on genetic 
changes to the DNA.  First, inverting the direction of the promoter for the operon 
encoding type 1 pilus, type 1 pili in E. coli phase vary (101).  Second, site specific 
insertion and precise excision of the insertion element also cause phase variation.  This 
mechanism maybe the cause of phase variation in capsule production in some N. 
meningitides (82). 
Besides changing the DNA sequence itself, phase variation can also happen by 
epigenetic regulation.  This mechanism involves modifying DNA by methylation.  
Methylation normally happens to the regulatory site.  These regulatory sites are DNA 
sequence targets of the regulatory proteins directly regulate transcription.  The binding of 
regulatory proteins to the target site either activate or repress the transcription.  The 
methylation status decides the binding status of regulatory protein the regulatory element.  
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This in turn affects the expression of the regulated gene.  It is found that the expression of 
pili in S. entericca Typhimurium and the P pili in E. coli are under this regulation (102, 
103). 
LATERAL GENE TRANSFER 
Genomic Variation in V. cholerae 
The genomes of V. cholerae exhibit substantial variation among conserved 
housekeeping genes, as indicated by multilocus enzyme electrophoresis (23) and multi 
locus sequencing typing (24, 25, 46).  In addition, studies on the pathogenic isolates of V. 
cholerae from the 6th, 7th and a U.S. coast epidemic suggest that, although the clones 
were closely related, there was evidence for homologous recombination (24, 29, 104).  
Garg et al. analyzed nine housekeeping loci in the 96 V. cholerae O139 isolates from the 
same hospital and identified 51 different sequence types.  Farfan et al. looked at the six 
house-keeping genes in the O139 Bengal isolates and found the 29 isolates fell into three 
different groups and therefore concluded that they may derive from different ancestral 
clones (29).  By extending the study to include environmental isolates, Aydanian et al. 
found 157 different genotypes in the MLST study with seven house keeping genes in 167 
isolates of V. cholerae.  The number of alleles with two of more nucleotide difference is 
much higher than expected from point mutation alone, suggesting lateral gene transfer.  
In contrast, a study using MLST has found the variation in the genomes of pandemic V. 
parahaemolyticus to be very limited and there was no evidence for recombination (105).  
This paradox suggested that the high plasticity of genome may be a unique character of 
V. cholerae, or at least it is not a common theme among all Vibrio.   
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In addition to the variation seen in conserved housekeeping loci, the V. cholerae 
genome also has several highly variable regions where non-homologous genes may be 
present or absent.  The regions include the Vibrio pathogenicity island (VPI) encoding 
TCP (31, 106), the cholera toxin gene cluster, the superintegron (20) and the surface 
polysaccharide biogenesis regions.  The high plasticity of the V. cholerae genome are 
clear evidence that lateral transfer plays an important role in the evolution of this species.  
Some of the lateral gene transfer mechanisms are known in V. cholerae, others remain to 
be investigated.  VPI is linked with a phage integrase, which suggests VPI may have been 
acquired into the genome by phage.  Cholera toxin is encoded in a prophage CTX∅.  
CTX∅ has been isolated as a free phage particle from the supernatant of V. cholerae 
culture (32).  Genes in the superintegron region may have been recruited by the integron 
structure.  The mechanism for the plasticity in the surface polysaccharide biogenesis 
regions is not well understood. 
 
Mechanism of Lateral Gene Transfer 
Exogenous DNA can enter a bacterial cell via several paths including transduction, 
conjugation and transformation.  All of these mechanisms have been shown to exist in V. 
cholerae.  Transduction is conducted by bacterial phage.  After phage transfect a host 
cell, it can have its genetic material replicated by the host replication system.  The genetic 
material is then packed into its protein coat.  The host cell then lyses and release phage 
particles.  The phage particles are ready for a new round of transfection.  There are two 
potential outcomes after a phage transfection.  First, phage can accidentally pack the host 
DNA and carry with it into the new host.  The genetic material carried from previous host 
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can recombined with its new host DNA by homologous recombination if their similarity 
permits.  Second, the phage DNA can insert into the host DNA by lysogeny.  Therefore, 
bacteria phage can introduce both its own genetic material and the genetic material from 
its previous host. 
Phage can insert into the host genome by lysogeny.  In this mechanism, phage plays 
a critical role in V. cholerae pathogenesis.  Cholera toxin is encoded in a prophage 
CTX∅.  CTX∅ has been isolated as a free phage particle from the supernatant of V. 
cholerae culture (32).  The incorporation of CTX∅ into V. cholerae genome is beneficial 
for the spread and propagation of the bacteria and differentiate epidemic V. cholerae to 
the non-epidemic V. cholerae.  The mobility of CTX∅ raises concerns for vaccine 
development, since certain vaccines of V. cholerae is a recombinant whole cell with 
mutated toxin genes (19).  Besides CTX∅, other virulence genes in V. cholerae may also 
related to phage, including VPI. 
Conjugation is the second major mechanism for exogenous DNA to enter a bacterial 
cell.  Conjuative plasmids are responsible for conjugations to happen.  DNA is mobile if 
they are in a plasmid.  Plasmid can enter bacterial cell by conjugation or transformation.  
V. cholerae has a sex factor similar to F factor, a P plasmid (107).  The conjugation 
plasmid F factor in E. coli can integrate into the genome stably and form a strain capable 
of high frequency recombination.  Unlike F factor, P factor can not integrate into the 
genome stably.  There are also a few plasmid belonging to the IncC incompatibility 
group, termed R factors, exist in V. cholerae (108, 109).  These plasmids are responsible 
for some of the increase of antibiotic resistance in V. cholerae.  Antibiotic resistances 
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genes introduced by plasmid have posed an enormous impact in health care and 
economic.   
The third major mechanism for bacteria to take up exogenous DNA is natural 
transformation.  One immediate benefit of this is probably to use the uptake DNA as 
nutrient (110).  In order for DNA to transform into bacteria, cells need to enter a 
competent state.  V. cholerae was considered not naturally competent up until recently.  
Schoolnik’s group showed that V. cholerae could be induced into a competent state by 
the presence of chitin (111) plus other factors including overgrowth and nutrient 
limitation.  The competence state requires the expression of a type IV pilus and a DNA 
binding protein as well as several regulatory cascades.  Chitin is abundant in its natural 
aquatic environment of V. cholerae.  Therefore V. cholerae is likely to be naturally 
competent on a regular basis. 
After entering the cell, in order to be inherited stably, foreign DNA needs to be 
integrated into the host genome.  This is achieved by homologous recombination or 
illegitimate recombination.  Homologous recombination is reciprocal; it requires the 
points of recombination of the DNA being exchanged have high similarity.  Homologous 
recombination depends on the activity of various Rec proteins.  In E. coli, it was found 
that the presence of a short nucleotide sequence, chi, promotes recombination (112, 113).  
Similarly, a DNA-uptake signal sequence has been identified from H. influenza, the 
Pasteurellaceae (114-116), N. gonorrhoeae and N. meningitides (117, 118).  These short 
sequences interact with both dsDNA exonuclease and RecBCD helicase.  These 
sequences attenuate DNA exonuclease activity, thus avoiding degradation of the invading 
DNA.  At the same time, these sequences provide a target for the RecBCD helicase and 
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promote recombination.  DNA-uptake sequence can be identified by an exquisite 
experiment designed by Sourice et al. (115), in which the presence of such sequence in 
random clone will prevent the formation of rolling circle plasmid, which depends on the 
activity of host exonuclease to excise the linear replication form into circular monomers.  
Illegitimate recombination, on the other hand, does not depend on the DNA 
similarity.  Multiple copies of the same element can integrate into the genome by 
insertion.  This procedure is normally depends on the activity of transposase, which 
maybe carried in phage DNA, insertion sequences, or transposons.  The insertion of 
CTX∅ is a good example of an illegitimate recombination.  Insertion sequences are 
frequently found in the region of polysaccharide biogenesis.  For example, an insertion 
sequence (IS1358) is present in the O1, O139 and O22 serogroup defining LPS region.  
Another insertion sequence is present in the O37 LPS biogenesis region. 
Integrons are gene capture systems that recombine exogenous gene cassettes and 
direct their expression.  They are first described by Stokes et al. in 1989 and since then 
investigated extensively because its role in antimicrobial resistance (119).  Integrons 
contain three key elements: i) an integrase gene, which recombines genes in a RecA 
independent manor; ii) a primary integration site attI; and iii) a promoter, which directs 
the transcription of a captured gene (120).  Integrons can link to a mobile genetic element 
such as insertion sequences, transposons and conjugative plasmids.  The mobilized 
integrons contribute significantly to the microbial antibiotic resistance.  These integrons 
are classified into five groups according to their integrase gene sequence (120):  Class1 
integrons are associated with Tn402 transposons; Class 2 integrons are related to Tn7 
transposons; Class 3 integrons may be located in a plasmid that is yet to be characterized.  
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Class 4 integrons in found as a subset of SXT element in Vibrio cholerae (121), confers 
trimethoprim resistance; Class 5 is in a plasmid carried transposon, found in Vibrio 
salmonicida, also confers trimethoprim resistance.  The mobilized integrons generally 
contains one to several gene cassettes downstream of their attI sites.  The gene cassettes 
all contain an imperfect repeat called attC site.  The sequences in different attC sites are 
not very conserved.  DNA recombination in integrons involves both the attI site and the 
attC site.   
A superintegron was first discovered from V. cholerae (122).  It is located on 
chromosome II.  Superintegrons share same genetic structures as integrons.  The 
integrase in the superintegron is related to the ones in the mobile integrons.  However, 
superintegron are different from the mobile integrons, which normally capture one to a 
few gene cassettes in that, a superintegron captures many gene cassettes.  The function of 
most of the gene encoded in the superintegron is not well characterized.  The attC sites of 
different gene cassettes in a superintegron are highly similar.  In V. cholerae, the attC 
sites are termed Vibrio cholerae repeats (VCRs).  The VCRs are 120-124 base pairs long 
and share more than 80% identity to each other.  Superintegrons have been discovered in 
many diverse bacteria species, including all of the Vibrio species examined, and some 
Pseudomonas sp., Xanthomonadaceae sp. etc.  It is proposed that mobile integrons may 
have involved from superintegrons with the capture of integrase gene and the attI site by 
a mobile genetic element (120).  This proposal has been supported by the experimental 
evidence that an integron mobilized on a plasmid can randomly recruit gene cassette from 
the superintegron of V. cholerae (123).  The presence of a superintegron provides an 
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onsite gene capture system for V. cholerae and may have contributed significantly to the 
evolution of this species, as will be shown in chapter 3. 
 
STUDY AIMS AND HYPOTHESIS 
The emergence of the O139 and O37 groups of V. cholerae indicated that new 
epidemic strains emerge by changing their surface polysaccharides including LPS and 
CPS, but with a relatively stable toxigenic background.  This phenomenon raises many 
questions including: 1) What is the genetic basis underneath the emergence of the new 
epidemic strain; 2) Will novel epidemic strains of V. cholerae emerge in the future? 3) 
What should we expect from the novel strain(s)? Does the capsule present a potential 
threat in the new strains? 
The predominant epidemic strain of serogroup O1 does not have a capsule, therefore 
the impact and genetic basis of capsules has received little attention.  O139 arose from 
O1 with a new O-antigen and a capsule, both consisting of the same repeating unit.  The 
capsule of O139 comes as a surprise and raises a potential septicemia threat.  The threat 
would have been greater if the capsule and the O-antigen were different entities, in which 
one antibody could not account for both antigens.  The demand to understand the genetics 
of capsule biogenesis in V. cholerae is urgent and critical.  This study was aimed at 
understanding, a) the genetic basis of capsule biogenesis in V. cholerae; b) the role lateral 
gene transfer plays in the emergence of new capsule and LPS genes, and in subsequently 
converting a strain to be pathogenic.  I initiated our study with the following hypotheses: 
A: In the genome of non-O1 V. cholerae, there is a distinct region for capsule biogenesis, 
different from the lipopolysaccharide (LPS) biogenesis region. 
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 B: Horizontal gene transfer plays a critical role in the evolution of V. cholerae, 
especially in maintaining diversity of surface polysaccharide. 
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CHAPTER II: THE CAPSULE BIOGENESIS GENES ARE EMBEDDED IN THE 
LPS REGION IN NON-O1 VIBRIO CHOLERAE NRT36S 
ABSTRACT 
V. cholerae serogroup O31 NRT36S, a human pathogen that produces a heat-stable 
enterotoxin (NAG-ST), is encapsulated.  The structure of the capsular (CPS) 
polysaccharide was determined by high resolution NMR spectroscopy and shown to be a 
complex structure with four residues in the repeating subunit.  The gene cluster of 
capsule biogenesis was identified by transposon mutagenesis combined with whole 
genome sequencing data (GenBank accession number DQ915177).  The capsule gene 
cluster shared the same genetic locus as that of the O-antigen of lipopolysaccharide (LPS) 
biogenesis gene cluster.  Other than V. cholerae O139, this is the first V. cholerae CPS 
for which a structure has been fully elucidated and the genetic locus responsible for 
biosynthesis identified.  The co-location of CPS and LPS biosynthesis genes was 
unexpected, and would provide a mechanism for simultaneous emergence of new O and 
K antigens in a single strain. 
INTRODUCTION 
Vibrio cholerae has three forms of surface polysaccharide, although some strains do 
not express all three forms: a lipopolysaccharide (LPS) inserted in the outer membrane, a 
capsule composed of high molecular weight polysaccharide that forms a dense thick coat 
outside of the bacterial cells, and a loose slime-like exopolysaccharide.  Unlike V. 
cholerae of serogroup O1, which causes cholera, most non-O1 isolates have capsular 
polysaccharide (CPS) in addition to lipopolysaccharide (LPS).  The LPS of V. cholerae is 
a protective antigen for cholera (19, 38), with over 200 serogroups identified based on the 
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O-antigen of the LPS.  The O-antigen biogenesis loci of 4 serogroups (O1, O139. O22, 
O37) have been sequenced and characterized, and have been found to reside between two 
genes, gmhD and rjg, in the genome (18, 41, 48, 49, 124).  More than 85% of non-O1 V. 
cholerae isolates have a capsule that is critical for virulence in extraintestinal infections 
(125).  However, in contrast to E. coli, in which extensive work has been done on capsule 
structure and genetics (with associated classification into groups by Whitfield and 
Roberts (64)), structures and the genetics of CPS in V. cholerae are poorly understood.  
The one strain for which data on capsule structure and genetics are available is the 
newly emerged epidemic strain V. cholerae O139.  This strain has a capsule that appears 
to have arisen from the replacement of the O1 antigen biosynthetic region with a new 
gene cluster in the genetic background of an O1 strain (41, 49), resulting in emergence of 
a strain to which the human population did not yet have immunity.  The capsule in O139 
is unusual in that it shares the same repeating subunit as the O-antigen (76, 126, 127).  
Therefore, the polysaccharide in O139 appears as both capsule and LPS and resembles 
the KLPS in the group 4 E. coli capsule (64). 
There are limited studies on the genetics of polysaccharide biogenesis for the genus 
Vibrio.  In V. vulnificus the CPS is a primary virulence factor and hence has been the 
target of more intensive study (128).  An operon including genes wza, wzb and wzc was 
identified as part of the CPS genes for V. vulnificus strain M06-24 (71, 129), consistent 
with the presence of a group 1 capsule.  The genetic loci for CPS were also identified in 
another strain of V. vulnificus 1003 (72).  A wzx/wzy system was present for 
polymerization and exporting the CPS.  However, the genetic region responsible for LPS 
biosynthesis has not been identified in V. vulnificus. 
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The elucidation of capsule structure and biogenesis is critical to understanding the 
evolution of surface polysaccharide and the internal relationship between the capsule and 
LPS in this species.  It also has clear implications for understanding the behavior of this 
species within human populations, as the ability to change these surface antigens to avoid 
host immunologic detection is a key feature underlying the ability of V. cholerare to 
cause pandemic disease.  Here, we report the covalent structure and studies of the 
biogenesis of the capsule in V. cholerae NRT36S. 
RESULTS AND DISCUSSION 
Structure of CPS 
Chromatographic results.  Analysis of the polysaccharide hydrolysate by HPAEC-
PAD (high performance anion exchange chromatography pulsed amperometric detector) 
indicates that it contains three major peaks in approximate molar ratios 1:2:1.  From 
comparison of the retention times of these peaks and the standards run under identical 
conditions it was determined that the NRT36S CPS contains one galactose (Gal), two 
glucosamine (GlcN) and one rhamnose (Rha) residues.  Carbohydrate analysis by GC of 
the trimethyl silyl methyl glycosides performed at the Complex Carbohydrate Research 
Center (CCRC) likewise indicates this same monosaccharide composition.  The results of 
methylation analysis, also performed at CCRC, are given in Table 2.1.  These results 
indicate that the major components of the hydrolyzed sample of methylated CPS sample 
represent 3-linked Rha, 4-linked GlcNAc, 4- and 6-linked GlcNAc and galactose which is 
3-linked, 4-linked (and small percentage 3- and 4-linked).  
NMR results.  NMR spectra of the native polysaccharide are complex, showing a 
number of peaks in the anomeric region which are not in simple stoichiometric ratios.  
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Likewise, the acetyl methyl region (2.0 – 2.3 ppm) shows approximately 10 peaks not in 
simple ratios suggesting that the polysaccharide may be heterogeneously substituted with 
O-acetyl functions.  Therefore the sample was treated with aqueous ammonium 
hydroxide, which is expected to cleave O-acetyl groups by mild base catalyzed 
hydrolysis.  The NMR spectra of the resulting sample (de-O-acetyl polysaccharide) 
showed only two peaks in the acetyl methyl region (2.06 and 2.09 ppm) and a greatly 
simplified pattern in the anomeric region with four distinct signals in the C-H HSQC 
spectrum (4.5 – 5.5 ppm 1H, 95-105 ppm 13C).  We show below that the peaks at 2.06 and 
2.09 arise from N-acetyl groups. 
Under the assumption that the HPAEC-PAD result indicates four sugar residues in 
the repeating subunit of the polysaccharide, the four signals were arbitrarily assigned 
identifying letters, A, B, C and D for the purpose of individual sugar identification using 
homonuclear 1H spin correlation.  Residue C is identified as rhamnose by the 
characteristic methyl resonance of the 6-deoxy sugar at 1.33 ppm in combination with the 
equatorial configuration of H2 indicated by its small homonuclear coupling constants.  
The anomeric configuration is identified as β - by large NOE (nuclear Overhauser) 
between H1, H3 and H5 as well as by 1JCH = 162 Hz.  Residues B and D are identified as 
amino sugars by the characteristic chemical shift of C2 and as glucosamine by 
homonuclear coupling values.  Residue B has the α-anomeric configuration as indicated 
by small JH1-H2 and by 1JCH = 172 Hz while residue D has the β- configuration as 
indicated by large JH1-H2 and by 1JCH = 158 Hz.  The fourth residue, A, is identified as α -
galactose on the basis of the chromatographic data, small JH1-H2 and 1JCH = 168 Hz.  The 
central part of the HSQC (heteronuclear single quantum coherence) spectrum of the de-
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O-acetyl polysaccharide is shown in Figure 2.1 and the complete 1H and 13C resonance 
assignments are given in Table 2.2.  The glycosidic linkages between the four residues 
were determined from HMBC (heteronuclear multiple bond coherence) and NOESY 
(nuclear Overhauser spectroscopy) data as indicated in Table 2.3.  While no HMBC 
peaks could be observed for the D-B linkage, the NOE data clearly indicate a β-1-6 
linkage and the downfield chemical shift of B-C6 at 68.9 ppm confirms this linkage 
assignment.  The proposed structure of the tetrasaccharide repeating unit is given in 
Figure 2.2. 
Having determined the structure of the sugar backbone, we turned to the acetylated 
forms of the polysaccharide.  While interpretation of their complex spectra was difficult, 
it was possible given the basic sugar structure.  Base hydrolysis milder than that required 
to produce the de-O-acetyl polysaccharide yielded a sample with NMR spectra having 
peaks in stoichiometric ratios (mono-O-acetyl polysaccharide).  The single O-acetyl 
group is assigned to the 2-position of rhamnose (C), a position resistant to base 
hydrolysis due to the absence of a neighboring hydroxyl function.   A complete set of 
homonuclear and heteronuclear NMR spectra of a sample of this form of the 
polysaccharide in H2O solution allowed assignment of signals of the amide protons of 
residues B and D confirming that they are N-acetyl amino sugars.  The complete 
assignment of the NMR spectrum of the mono-O-acetyl polysaccharide is given in Table 
2.4. 
The acetate methyl region of the NMR spectrum of the native, untreated, 
polysaccharide shows a number of peaks including those assignable to the amides of 
residue B and D and of the 2-O-acetyl group of residue C along with smaller peaks 
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indicating partial O-acetylation at other positions.  Using HMBC spectra, it was possible 
to correlate methyl proton signals, through carbonyl carbon resonances, to sugar ring 
protons indicating positions of acetyl substitution.  In addition to the 2-O-acetyl of 
residue C, it was possible to identify an O-acetyl group on the 3-position of residue B to 
the extent of about 50% as indicated in Table 2.5.  Anomeric resonances of residue A 
were split into three peaks in the native polysaccharide suggesting partial O-acetylation 
of that residue but the exact positions could not be definitively assigned. 
In considering our interpretation of the structural data, it should be pointed out that 
the methylation data (Table 2.1) are not entirely consistent with the NMR data and the 
structure proposed in Figure 2.1.  While the methylation data indicating 3-substituted 
rhamnose, 4- and 4,6- substituted glucosamine are consistent with the proposed structure, 
the latter implies terminal galactose.  The methylation data indicate 3 and 4 substituted 
galactose and we are not able to identify any substituents expected to survive the strongly 
basic conditions of per-O-methylation.  The NMR data can be used to rule out any 
common C,H substituents such as pyruvate or lactate and 31P spin-echo-difference spectra 
showed no indication of phosphates.  Sulfate analyses were likewise negative.  At this 
point, the best explanation we can offer is undermethylation resulting from some steric 
effects in this novel structure. 
The structure proposed here for the NRT36S capsule repeating subunit is very 
similar to that reported for the V. cholerae O6 lipopolysaccharide (130).  The 
polysaccharide backbones are identical but with stoichiometric O-acetylation at both C2 
of rhamnose and at C3 of α-GlcNAc and the side chain is α-GlcA for this latter structure.  
While no genetic data are available for this O6 strain, we predict considerable homology 
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of the O-antigen clusters suggesting the possibility of lateral transfer between these two 
strains. 
Transposon mutagenesis and mutant selection 
The conjugations between wild type Vibrio cholerae NRT36S and donor strain E. 
coli S17λpir/putKm-2 generated 20,615 mutants of NRT36S, each carrying a single copy 
of the transposon Km-2 in its genome.  Among these mutants, 411 colonies displayed a 
translucent phenotype on LB agar.  This phenotype suggests that genes involved in 
capsule biogenesis have been disrupted by the transposon (50). 
DNA analysis of mutants 
Genomic DNA was isolated from the translucent mutants and analyzed by inverted 
PCR and sequencing, identifying 13 unique insertion sites in 11 genes.  Since NRT36S 
can also undergo spontaneous phase variation between translucent and opaque colony 
morphologies, isolates with the 13 insertions were tested for complement resistance (50).  
Nine insertions in eight genes were sensitive to serum killing and showed no reversion to 
the opaque morphology (Table 2.6).  Isolates with insertions in the other 3 genes reverted 
to opaque colonies and were resistant to serum killing and therefore were excluded from 
further analysis.  Only four of the stable mutant genes related to sugar modification and 
processing and were considered as putative structural genes for the biogenesis of the 
NRT36S capsule.  The function of the other genes was unclear.  One of the putative 
structural genes had a homolog in the fully sequenced genome of V. cholerae N16961, a 
serogroup O1 pandemic strain.  Orf23, a homolog of VC0262, an UDP-glucose 4-
epimerase (galE) was disrupted in translucent colony TR3.  TR3 was restored to opaque 
phenotype and resistant to serum killing when complemented with galE gene.  The other 
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three structural genes identified by transposon mutagenesis did not have homolog in the 
genome of V. cholerae N16961.  In translucent colony TR17, a glycosyltransferase gene 
was disrupted and a rhamnosyltransferase gene was disrupted in both TR43 and TR287.  
An ABC transporter system integral membrane protein gene wzm was disrupted in 
TR296.  The VC0262 homolog and the 3 other genes are typical of genes commonly 
found in polysaccharide biogenesis. 
Immuno blotting and size exclusion chromatography 
Size exclusion chromatography (SEC) data indicated that the molecular weight of 
the NRT36S capsule is greater than 670k Dalton (Figure 2.3A).  The antiserum raised 
against the whole cell of V. cholerae NRT36S did not detect anything close to that 
molecular weight of CPS in the immuno blot (Figure 2.4), indicating that the antibodies 
did not react with the capsule.  This result was consistent with the previous finding (131).  
Nevertheless, the antibodies detected some polysaccharides that form a ladder pattern in 
the molecular weight range of 20k to 40k Dalton (Figure 2.3B).  We believed these were 
the LPS.  Interestingly, the amount of reactive LPS to the antibody was reduced in 
mutants TR3, TR17, and TR296.  Analysis of the capsule preps by SEC from the mutants 
showed that three of the mutants, TR3, Tr287 and TR43 had completely lost the high 
molecular weight peaks corresponding to the capsule while in TR17 and TR296, the 
amount of capsule was significantly reduced (Figure 2.3). 
Electron microscopy 
We evaluated thin sections of wild type V. cholerae NRT36S and several 
translucent mutants stained with polycationic ferritin by electron microscopy (EM).  
Representative profiles are shown in Figure 2.5.  As seen before ((50), NRT36S 
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displayed a heavy, complete capsule surrounding the cell.  TR3 did not have a complete 
capsule, but had some patches of capsule materials.  Both of TR17 and TR296 had a 
much thinner capsule compared to opaque NRT36S.  EM pictures for all three mutants 
were consistent with the amounts of capsule observed by SEC (Figure 2.3B). 
Sequencing of the V. cholerae NRT36S genome 
V. cholerae NRT36S genome was sequenced by the company 454 Life Sciences.  
The sequencing runs have generated 1,082,967 reads and output 104,531,256 bps of 
sequences.  The estimated coverage depth was 26X.  The draft genome consisted of 184 
contigs with total length of 3.9 million base pairs.  The average GC content for the draft 
genome was 47.5%.  The draft genome was annotated.  For the purpose of the discussion 
in this paper, only those features related to the polysaccharide biogenesis will be 
discussed.   
Genetics of the polysaccharide biogenesis 
O-antigen region.  In previous studies, the O-antigen biogenesis genes for V. 
cholerae had been identified to cluster at one locus in the genome, between genes gmhD 
and rjg (18, 47-49).  After aligning the contigs of the draft genome of V. cholerae 
NRT36S to the fully sequenced genome of V. cholerae N16961 (20), we found that 3 
contigs (contigs 34, 19, 78) of NRT36S could partially align to the O-antigen region of 
N16961.  Contig 34 contains gmhD gene and contig 78 contains rjg gene.  Contig 19 falls 
into the middle of contig 34 and 78.  The sequence information from analyzing the 
transposon mutagenesis mutants was able to pick up two more contigs (contig 98 and 43) 
and connect them to contig 19.  Therefore gmhD and rjg were separated by 5 contigs in 
the NRT36S genome.  The gaps between these contigs were filled and we ratified this 
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region, between gmhD and rjg, as the putative O-antigen biogenesis region (Figure 2.6) 
for V. cholerae NRT36S.  The sequence between gmhD and rig was deposited into 
GenBank (accession number DQ915177). 
CPS region.  We located the capsule biogenesis genes identified by transposon 
mutagenesis in the NRT36S genome (Table 2.6).  To our surprise, the 4 putative capsule 
structural genes identified by transposon mutagenesis were all located between the genes 
gmhD and rjg, the region considered to encode O-antigen biogenesis (Figure 2.6.).  
Theses four genes were knocked out by at least one of 5 independent transposition events 
and caused the translucent phenotype associated with the loss of the capsule in each case.  
Therefore, we believe that the O-antigen biogenesis region in V. cholerae NRT36S is also 
the capsule biogenesis region.   
Global features.  The locus of CPS/O-antigen was 49,916 base pairs in length 
between genes gmhD and rjg.  There were 46 open reading frames (orf) (Figure 2.6).  
The annotation for each orf is listed along with a match from GenBank and its percent 
amino acid identity/positive, the species and the E-value (Table 2.7).  Twelve genes were 
glycosyltransferases, 16 genes were recognized as pathway genes for synthesis of the 
nucleotide sugar precursor for external polysaccharide, and 6 other genes were 
recognized as polysaccharide processing and translocation genes.  The function of the 
other 12 genes was unknown.  A JUMPstart site (132) was located just downstream to the 
gmhD gene.  The GC content of this region was 41.2%, lower than the 47.5% GC content 
of the genome.  The disruption by transposon in orf5 (wzm), an ABC transporter gene, 
orf8, a glycosyltransferase gene, orf23, an UDP-glucose-epimerase, (galE) and orf43, a 
rhamnosyltransferase gene had caused the non-encapsulation of NRT36S (Figure 2.3).  
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The complementation by galE gene reverted the translucent mutant TR3 to opaque 
phenotype and the complemented colonies were resistant to serum killing. 
Glycosyltransferases.  There were 12 glycosyltransferase genes identified.  The 
precise function of most of them remained to be elucidated.  Orf45 (wecA) was an 
undecaprenylphosphate N-acetylglucosamine 1-phosphate transferase gene. WecA was 
putatively the initial transferase to catalyze the transfer of N-acetylglucosamine 1-
phosphate to UndP in the capsule polysaccharide synthesis. 
Synthesis genes.  The structural data for V. cholerae NRT36S indicate that the 
capsule contains, one residue each of rhamnose and galactose and two N-acetyl-
glucosamine residues, genes for whose synthesis are present in the CPS region.  There are 
two sets of genes that are almost identical (orf1-4, and orf33-36) for L-rhamnose 
synthesis; they were rmlB, rmlA, rmlC, and rmlD in the order.  L-rhamnose is commonly 
present in bacterial polysaccharides and the genes to synthesize it are normally clustered 
(133).  Orf43 may be the rhamnosyltransferase to catalyze the addition of rhamnose to 
the CPS backbone.  The disruption orf43 by the transposon both resulted in the loss of the 
capsule.  Orf23 was gene galE; its product UDP-glucose 4-epimerase catalyzed the 
conversion of UDP-glucose to UDP-galactose.  The disruption of galE gene in mutant 
TR3 caused the loss of the capsule.  Orf24 (wbeW) transfers galactose to the capsule 
complex.  Orf 41, a sugar O-acetyltransferase homologue could be involved in the 
observed O-acetylation of the capsule, but this modification of bacterial polysaccharides 
is not well understood and other genes may be involved as well.  Orf11, 12, 22, 37, 41 
and 44 were also putative pathway genes for the synthesis of nucleotide sugar precursors, 
but their precise functions were not clear to us. 
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Translocation and processing genes.  An ABC-2 type transporter system consisted 
of wzm and wzt were present in the CPS/O-antigen region.  When wzm was disrupted by 
transposon mutagenesis, the mutant was non-capsulated (Table 2.6).  Orf38 was predicted 
as a polysaccharide translocase gene wzx.  Orf40 was predicted to have several 
transmembrane domains by the Dense Alignment Surface (DAS) program (134) and were 
assigned as putative wzy.  Three genes wza, wzb and wzc were also present in the CPS/O-
antigen region.  The proteins Wza, Wzb and Wzc in E. coli formed a system that was 
involved in the exportation of E. coli group 1 capsular polysaccharides (135).  
The disruption of an ABC transporter system integral membrane protein gene wzm 
had significantly reduced the amount of capsule (Figure 2.3) in our experiments and 
resulted in the translucent colonies that were susceptible to serum killing.  Examination 
of the CPS region also revealed the existence of wzt, which is another component of the 
ABC transporter system.  Our results suggest that the processing and translocation of the 
capsule in V. cholerae NRT36S involves the ABC transporter system.  There was a recent 
report that an ABC transporter system was involved in the transportation of hetero-
polysaccharides in the O-antigen of E. coli O52 (136).  Our results may be another case 
where an ABC transporter system was involved in the transportation of a hetero-
polysaccharide. 
Sharing of the same region by CPS and LPS.  The O-antigen genes had been 
identified for 4 serogroups in V. cholerae, including O1, O139, O22 and O37 (figure 2.7) 
(18, 47-49, 124).  In these serogroups, the gene cluster for O-antigen biogenesis all 
resided between the genes gmhD and rjg.  In our study of V. cholerae NRT36S genome, 
there was a gene cluster identified as the LPS core biogenesis region upstream of the 
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gmhD gene (data not shown).  There was also another gene cluster in the genome that 
was identified as the rugose-associated exopolysaccharide biosynthesis region (data not 
shown).  The homolog of these genes were recognized as exopolysaccharide genes that 
related to the rugose phenotype in V. cholerae O1 El Tor (77).  Besides these regions, i. 
e., the LPS core genes and the rugose exopolysaccharide genes, there were no other 
significant gene clusters for polysaccharide synthesis in the genome of V. cholerae 
NRT36S.  All of this evidence supported the conclusion that the CPS region, i.e. the 
region between gmhD and rjg genes, is indeed also the O-antigen gene cluster.  The 
immuno blot showed that the LPS had been altered in the non-encapsulated mutants.  
That not only confirmed the sharing of the CPS and LPS region, but also indicated that 
some genes may be shared by the biogenesis of the two polysaccharide structures. 
To our surprise CPS and O-antigen shared the same genetic locus in V. cholerae 
NRT36S.  This differs from the organization of CPS and O-antigen gene clusters in E. 
coli.  In E. coli, CPS gene clusters and the O-antigen gene clusters are different (64).  The 
CPS genes from other gram-negative bacteria including Haemolyticus influenza, 
Salmonella typhi and Neisseria meningitidis have been cloned and characterized (69, 
137-141).  The organizations of most of them resemble E. coli.  No LPS genes have been 
reported to embed inside the CPS gene cluster for these species except in N. meningitides.  
In N. meningitides group B, the mutations of two CPS biosynthesis genes (synX or synC) 
and another gene next to the CPS region, galE gene, were shown to affect the 
lipooligosaccharide structure (138, 141).  The CPS and O-antigen in group 4 E. coli 
consist of the same molecule.  This arrangement is also seen in V. cholerae O139 where 
CPS and O-antigen are encoded by the same genetic locus and have identical repeating 
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subunits.  NRT36S is an O31 serogroup.  Kondo’s group found that the LPS of O31 in V. 
cholerae contains L-glycero-D-mannoheptose, glucose, fructose, galactose, glucosamine 
and an unknown amino sugar A2 (142).  L-rhamnose was not found in the LPS, while our 
study found L-rhamnose in the CPS, suggested that CPS and LPS are two distinct 
structures in V. cholerae NRT36S.  The antiserum against NRT36S detected LPS but not 
the capsule, again suggested that the O-antigen and CPS were two different entities.  Our 
finding represents a new type of genetic organization of polysaccharide genes and raises 
a question of differential regulation of the genes for expression of capsule and O-antigen 
polysaccharides. 
The genes for bacterial surface polysaccharide biogenesis were typically found in a 
cluster with an atypical GC content compared to the rest of the genome (143).  It had 
been suggested that bacteria could convert to a new serogroup by acquiring a new O-
antigen biogenesis region.  There was abundant evidence that V. cholerae O139 arose 
from an O1 strain by receiving a new O-antigen gene cluster (15, 27, 41).  The sharing of 
CPS and O-antigen in V. cholerae, as indicated in our findings, makes this region one 
interchangeable unit.  It is possible that V. cholerae can acquire a new gene cluster and 
give rise to a new strain with an O-antigen and K-antigen at the same time, both 
unrecognizable to the host immune system.  This, in turn, may be a key element in its 
ability to cause pandemic disease, permitting rapid emergence of new strains that can 
escape immunologic detection by host populations. 
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EXPERIMENTAL PROCEDURES 
Bacterial strains and culture conditions 
V. cholerae NRT36S is an isolate originally cultured from a Japanese patient with 
travelers’ diarrhea.  It is serogroup O31, cholera toxin (CT) negative and produces a heat 
stable enterotoxin NAG-ST (144). When fed to volunteers this strain caused diarrhea, 
including, in one patient, a 5.3-liter diarrhea purge (41).  Wild type V. cholerae NRT36S 
produces a capsule (50).  This strain is resistant to polymycin B but sensitive to 
kanamycin. 
Transposon mini-Km2 was carried in the plasmid putKm-2 and maintained in the 
host strain E. coli S17λpir.  Mini-Km2 was found to randomly transpose into the genome 
of the recipient strain with a single transposition.  Mini-Km2 encodes a gene for 
kanamycin resistance. (145, 146) 
Cultures were maintained in L broth with 15% glycerol at -70°C.  Bacteria were 
cultured in the L broth or agar at 37°C unless otherwise stated.  Appropriate antibiotics 
were added in concentrations: 50 mg/ml Kanamycin, 50 unit/μl polymycin B. 
Isolation and purification of CPS 
Frozen stock of NRT36S was streaked for isolation on L agar in 150-mm Petri 
dishes and incubated overnight at 37 0C.  A single bacterial colony from the plate was 
inoculated into 10 ml of L-broth for 18 h of growth at 37 0C.  One ml of the culture was 
then inoculated into one liter L-broth and incubated overnight at 37 0C.  Bacterial cells 
from eight 1-liter batches of culture were pelleted at 10,000g and re-suspended in 120 ml 
of 0.5X phosphate-buffered saline pH 7.5 and shaken at 200 rpm on a rotary shaker for 2 
h at room temperature.  The bacterial suspensions were centrifuged to remove cell debris 
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at 16,000g for 20 minutes at 4 0C and the supernatant dialyzed with multiple changes of 
distilled water and concentrated two fold by ultra filtration (100,000-nominal-molecular-
weight stirred cell; Amicon, Beverly, Mass). The retentates were then ultra centrifuged at 
154,000g for 2h at 20 0C and the supernatants were removed and digested with RNase A 
(100 ug/ml) and DNase 1 (50 ug/ml plus 1mM MgCl2) for 2h followed by a 3h digestion 
with proteinase K(250 ug/ml) and phenol-chloroform extraction.  The aqueous layer was 
dialyzed as described above, and the resultant sample was lyophilized.  Purity of the CPS 
was assessed by bicinchoninic acid protein assay (MicroBCA, Pierce Chemical Co., 
Rockford Ill.), and Limulus amoebocyte lysate assay (Sigma Chemical Co., St. Louis, 
Mo.) and by NMR.    
HPAEC-PAD 
Carbohydrate composition was determined by HPAEC on Dionex HPAEC.  A 2 mg 
sample of polysaccharide was hydrolyzed in 1ml of 1 M trifluoroacetic acid (TFA) at 
100°C for 3 hours.  The sample was dried with nitrogen and redissolved in 200 µL of 
dH2O and submitted to HPAEC-PAD analysis with a Dionex CarboPack PA-10 (4 mm) 
column and detected on ED40 pulsed amperometric detector.  The mobile phase used was 
15 mM NaOH at 1 ml/min.  The retention times were matched with those of standard 
monosaccharides run under identical conditions.  
Deacylation and preparation of samples for NMR 
A sample of 15 mg of CPS in 0.6 ml D2O was subjected to deacylation by 0.3 M 
ammonium hydroxide for 6 days at 25 C.  The 1D 1H spectrum was monitored daily and 
the sample was lyophilized, exchanged with 99.9% D2O and made up with 0.6 ml pure 
D2O (de-O-acetyl polysaccharide).  A second sample was prepared with milder base 
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treatment in 0.03 M ammonium hydroxide for 5 days at 4 C (mono-O-acetyl 
polysaccharide).  For detection of amide protons, a sample was subjected to deacylation 
(without D2O exchange) and made up with 0.6 ml 90:10 (v/v) H2O:D2O. 
Transposon mutagenesis 
Conjugations were performed between V. cholerae NRT36S as the recipient strain 
and E. coli S17λpir/putKm2 as the donor strain.  Ten μl overnight culture of V. cholerae 
NRT36S was spotted on LB agar and let dry, 10 μl overnight culture of S17λpir/putKm2 
was then spotted on top.  After overnight incubation at room temperature, the mixture 
was re-suspended in 1 ml of LB broth; 50 μl of the suspension was plated onto LB agar 
with kanamycin and polymycin B to select for V. cholerae mutants.   
DNA analysis 
DNA flanking the transposon in the mutants was amplified and sequenced by a 
modified inverse polymerase chain reaction (PCR) protocol (147).  Genomic DNA was 
isolated with PrepManTM (Applied Biosystems) according to the manufacturer’s 
instruction.  Two μl genomic DNA of the above preparation was digested with 5 units of 
Nla III (New England Biolab) in a 20 μl reaction overnight followed by denaturing at 
65°C for 15 minutes.  Two μl of the digested DNA was self-ligated with 5 units of T4 
DNA ligase (Invitrogen) in a 10 μl reaction.  One micro liter of this solution was used as 
PCR template.  Two primers were designed to anneal to the transposon mini-Km2, 
pointing outwards to amplify the flanking sequence of the mutant genomic DNA.  The 
sequences of the primers are, L8 (reverse), GTACCGAGCTCGAATTCGGCCTAG; and 
L9 (forward), GGAGAAAACTCACCGAGGCAGTTC.  PCR was performed in a 30 μl 
reaction containing 100 μM of each dNTP, 1.5 mM of MgCl2, 1x PCR buffer 
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(Invitrogen) and 1 unit of Taq DNA polymerase (Invitrogen).  PCR products were 
purified with the Multiscreen PCR plates (Millipore) and sequenced using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).  The resulting fragments 
were separated and recorded in an ABI 3730x1 automatic sequencer (Applied 
Biosystems).  DNA sequence was then analyzed by the PHRED and PHRAP software 
(148-150). 
Complement resistance and Electron Microscopy 
Translucent colonies were challenged with complement in human serum as 
previously described (50).  Electron Microscopy (EM) was also performed as described 
(50). 
Size Exclusion Chromatography (SEC) 
Capsule preps were analyzed by SEC using a Beckman Coulter 32 Karat HPLC, 
with TSK gel column (JOSOHAAS; G3000SWxL; 10um; 30cmx7.5mm), and detected at 
200nm wavelength.  Purified NRT36S capsule was the same sample as for doing NMR.  
Capsule preps were prepared as followed: The amount of 109 cells was harvested into 
0.5X PBS and shaken for 2 hours in a rotary shaker at 250rpm followed by centrifuge at 
12000g for 20min.  The supernatant was treated with Dnase I and Rnase, followed by 
protease.  The supernatant was then extracted with phenol-chloroform and precipitated 
with ethanol.  The pellet was re-suspended in water and 1/3 of the amount was loaded.   
Immuno Blotting 
Immuno blotting was performed as described (47).  Circa 5x106 bacterial cells were 
treated with protease.  Washed whole cell lysates were run on 16% SDS-polyacrylamide 
gel and transferred to Immun-Blot PVDF membrane (BioRad, Hercules, CA).  Blots were 
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blocked in PBS contains 3% non-fat dry milk and then incubated for 1h in 1:1000 rabbit 
antiserum specific for V. cholerae NRT36S.  The blots were washed three times with 
PBS and incubated with alkaline phosphatase-conjugated goat anti-rabbit immunoglobin 
G (Sigma) at 1:10,000 in PBS for 1h.  The blot was washed five times with PBS and 
developed with Western Blue colorimetric detection solution (Promega). 
Sequencing of V. cholerae NRT36S genome 
The genome of NRT36S was sequenced by the company 454 Life Science (454 Life 
Science, Branford, CT) (151).  The contigs of the draft genome was compared and 
aligned to the fully sequenced genome of V. cholerae N16961 (20) by Blastn (152).  
Gaps between contigs were filled only for the capsule biogenesis region, which contained 
the genes identified by transposon mutagenesis.  Primers were designed for PCR to 
amplify the fragments of the gaps.  PCR products were then sequenced. 
Sequence analysis and annotation 
Open reading frames were predicted by the program GLIMMER (153) using the 
DasSarma Laboratory Autoannotation Pipeline (DLAP) (http://halo.umbi.umd.edu/.  
DasSarma et al., manuscript in preparation).  The settings in Glimmer were as in default, 
with the minimum gene size to be 90 bps and overlapping to be less than 30 bps.  BlastX 
program (152) was used for a similarity search against the protein database in NCBI.  We 
also used Artemis (154) to edit and confirm the results of GLIMMER. 
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Figure 2.1.  HSQC spectrum of the de-O-acetylated capsular polysaccharide from 
NT36S.  Signals from the anomeric and methyl group region are not shown.  The strong 
signal at 3.78, 60 ppm is a low molecular weight impurity. 
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Figure 2.2. Proposed structure of NRT36S CPS repeating unit.  Parentheses indicate 
partial O-acetylation of residue B at the 3-position. 
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Figure 2.3. Size Exclusion Chromatography of the capsule prep.  
A). Capsule prep from control (NRT36S and A5) compared to purified CPS of NRT36S.  
The size was estimated by thyroglobulin.  NRT36S is O31 and encapsulated.  A5 is also 
O31 but acapsular.  The arrow indicates the peak of the capsule at about 13.2 minutes 
retention time, which corresponds to about 670k Dalton molecular weight.  B). Capsule 
prep from mutants and control.  Tr296, Tr17, Tr43, Tr287 and Tr3 are translucent 
mutants generated by transposon mutagenesis.   
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Figure 2.4.  Immuno blotting.  5X106 cells were washed with 0.5X phosphate buffer 
saline and treated with DNase I, RNase and protease.  Washed whole cell lysates, 
separated on 16% SDS-polyacrylamide gel, were probed with antiserum specific for V. 
cholerae NRT36S.  Tr3, Tr17, Tr43, Tr287, Tr296 are translucent mutants of NRT36S 
generated by transposon mutagenesis.  A5 and NRT36S are both serogroup O31.  A5 is 





Figure 2.5. Thin sections of V. cholerae NRT36S and its translucent mutants stained with 
polycationic ferritin. (A) Wild type NRT36S; (B) Tr3; (C) Tr296; (D) Tr17. Bar, 200nm. 
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Figure 2.6.  Map of the CPS/O-antigen region of V. cholerae NRT 36S.  Diamond 
indicates JUMPstart site.  Black arrows indicate transposon insertion sites in the 
translucent mutants.  These insertions caused the loss or reduction of capsule 
polysaccharide.  Design patterns of open reading frames indicate different classes of 
genes: vertical lines, pathway genes; diagonal lines, processing and transportation genes; 




Figure 2.7.  A schematic representation of CPS/O-antigen biogenesis regions in V. cholerae.  The CPS/O-antigen biogenesis genes are 
between gmhD and rjg (black boxes).  GalE and wbeW (blue boxes) are conserved in all the serogroups. Wzm gene is conserved in all 
serogroups; wzt is conserved in O1, O37, and O31 serogroups. The CPS/O-antigen regions between O139 and O22 are very similar; 
grey boxes indicate conserved genes; white boxes indicated genes that are not conserved between O139 and O22.   
Table 2.1.  Results of methylation analysis. 
 
Glycosyl residue Percentage present 
3-linked Rha 25 
terminal Gal 4 
3,4-linked Rha 2 
3-linked Gal 13 
4-linked Gal 8 
4-linked Glc 3 
2- and 4-linked Gal 3 
3- and 4-linked Gal 4 
3- and 6-linked Gal 4 
4- and 6-linked Gal 1 
terminal GlcNAc 2 
4-linked GlcNAc 17 
4- and 6-linked GlcNAc 14 
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Table 2.2.  Complete assignment of the NMR spectra of the de-O-acetylated 
polysaccharide 
H-1 H-2 H-3 H-4 H-5 H-6, H-6’ NRT36 (deOAc) 
~50 °C 
(321 K) C-1 C-2 C-3 C-4 C-5 C-6 
5.19 3.66 3.67 3.50 3.97 3.79 A: 
α-D-Gal 
101.9 72.7 73.8 72.7 74.1 61.7 
5.01 3.93 4.05 3.64 4.16 4.09, 3.71 B: 
α-D-
GlcNAc 95.5 53.9 72.0 80.2 69.9 68.6 
4.85 4.16 3.61 3.42 3.40 1.33 C: 
β-L-Rha 
101.3 68.6 79.1 71.2 72.9 17.6 
4.42 3.78 3.67 3.67 3.49 3.83, 3.92 D: 
β-D-
GlcNAc 102.3 56.3 74.7 77.6 75.3 61.7 
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B-C BH1-CC3 BH1-CH2 
BH1-CH3 
C-D CH1-DC4 CH1-DH4 




Table 2.4. Complete assignment of the NMR spectra of the mono-O-acetylated 
polysaccharide.  Shifts enclosed in parentheses are those of the 3-O-acetylated B residue 
in the native polysaccharide. 




~50 °C  C-1 C-2 C-3 C-4 C-5 C-6 
5.15 3.63 3.67 3.51 3.95 3.76 A: 
α-D-Gal 
















(74.3) 80.3 68.6 68.4 
5.04 5.53 3.80 3.48 3.49 1.36 C: 
β-L-Rha 
99.9 69.9 76.3 71.6 73.2 17.6 




2.1 56.3 74.7 77.8 75.1 61.7 
 
 59
Table 2.5. Complete assignment of the NMR spectra of the NAc and OAc. 
assignment of NAc’s, 
OAc’s NH C=O CH3
B: 
α-D-GlcNAc 7.79 176.88 22.93; 2.03 
D: 
β-D-GlcNAc 8.09 175.24 23.19; 2.08 
C: 
β-L-Rha OAc  174.22 21.26; 2.21 
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Table 2.6. CPS genes identified by transposon mutagenesis 
Clone # Gene in 
CPS region 
Putative gene functions Best hit (AAI) 
TR2 not CYS regulon transcriptional activator V. cholerae (100%) 
TR23 not FadR fatty acid metabolism rgulator 
protein 
V. cholerae (100%) 
TR286 not Adenylate cyclase V. cholerae (100%) 





V. cholerae (98%) 




Orf43 Rhamnosyltransferase Shewanella sp. 
(66%) 






Table 2.7. Genes in the CPS/O-antigen biogenesis region 







epimerase 99/99 Vibrio cholerae 1.00E-180
1 rmlB 
DTDP-D-glucose-4,6-
dehydratase 99/99 Vibrio cholerae 0 
2 rmlA 
Glucose-1-phosphate 
thymidylyltransferase 100/100 Vibrio cholerae 1.00E-167
3 rmlD 
DTDP-6-deoxy-L-
mannose-dehydrogenase 99/99 Vibrio cholerae 1.00E-169
4 rmlC 
DTDP-6-deoxy-D-
glucose-3,5-epimerase 100/100 Vibrio cholerae 1.00E-104
5 wzm 
 ABC transporter system 
integral membrane 
protein 55/77 Raoultella terrigena  1.00E-81 
6 wzt 
ABC transporter system 
ATPase component  43/59 Nitrosospira multiformis 8.00E-86 
7   glycosyltransferase 32/49 Rubrobacter xylanophilus 2.00E-24 
8   glycosyltransferase 40/57 Nitrosospira multiformis 1.00E-125
9   glycosyltransferase 41/57 Burkholderia fungorum  1.10E-127
10   glycosyltransferase 38/56 Burkholderia sp.  8.00E-56 
11   
dTDP-glucose-4-keto-6-
deoxy-D-glucose 
reductase 39/64 Actinobacillus actinomycetemcomitans 4.00E-21 
12   
probable acetyl 
transferase by domain 30/46 Cellulophaga sp. 0.049 
13   hypothetical protein       
14   
3-hydroxybutyryl-CoA 
dehydrogenase 48/68 Pseudoalteromonas haloplanktis 2.00E-70 
15   Hypothetical protein       
16   glycosyltransferase 27/44 Syntrophus aciditrophicus 9.00E-06 
17   Hypothetical protein       
18   hypothetical protein       
19   
putative glycosyl 
transferase 55/69 Pseudomonas fluorescens 8.00E-97 
20   
UDP-N-
acetylglucosamine 2-
epimerase 67/82 Yersinia intermedia 1.00E-147
21   glycosyltransferase 96/97 Vibrio cholerae 2.00E-93 
22   
nucleoside-diphosphate 
sugar epimerase 99/99 Vibrio cholerae 0 





VC0263 99/99 Vibrio cholerae 4.00E-91 
25   
Trypsin-like serine 
proteases 96/97 Vibrio cholerae 1.00E-123
26 wbfB hypothetical protein 99/99 Vibrio cholerae 0 
27 wbfC 
hypothetical protein 
wbfC, periplasmic 97/97 Vibrio cholerae 1.00E-141
28 wbfD 
hypothetical protein 
wbfD 98/98 Vibrio cholerae 1.00E-112
29   hypothetical protein 52/58 Vibrio cholerae 6.00E-12 
30 wza 
Periplasmic protein 
involved in capsular 
polysaccharide export 67/82 Vibrio splendidus 1.00E-151
31 wzb 
Protein-tyrosine-
phosphatase 75/88 Vibrio vulnificus 6.00E-59 
32 wzc 
Putative tyrosine-protein 
kinase Wzc 75/87 Vibrio vulnificus  0 
33 rmlB 
dTDP-D-glucose-4,6-
dehydratase  98/98 Vibrio cholerae 0 
34 rmlA 
glucose-1-phosphate 
thymidylyltransferase  100/100 Vibrio cholerae 1.00E-167
35 rmlD 
dTDP-6-deoxy-L-
mannose-dehydrogenase 99/99 Vibrio cholerae 1.00E-169
36 rmlC 
DTDP-6-deoxy-D-
glucose-3,5-epimerase 92/94 Vibrio cholerae 1.00E-88 
37   O-acetyltransferase 38/58 Enterococcus faecalis 8.00E-17 
38 wzx O-antigen translocase 30/48 Pelodictyon luteolum  2.00E-39 
39   glucosyltransferase 34/53 Pseudoalteromonas tunicate 1.00E-39 
40  wzy 
Putative saccharide 
polymerase       
41   
Putative sugar 
acetyltransferase  51/72 COG0110, Cytophaga hutchinsonii 7.00E-43 
42   glycosyltransferase 29/53 Cytophaga hutchinsonii 5.00E-41 
43   Rhamnosyltransferase 66/77 Shewanella sp. 1.00E-113
44 Ugd 
UDP-glucose 6-




phosphate transferase 96/99 Vibrio cholerae 1.00E-157
46   Hypothetical protein 96/96 Vibrio cholerae 2.00E-63 
47 rjg 
Predicted exonuclease of 
the beta-lactamase fold 
involved  in RNA 
processing  98/99 Vibrio cholerae 0 
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CHAPTER III: THE GENOME OF NON-O1 VIBRIO CHOLERAE NRT36S 
DEMONSTRATES THE PRESENCE OF PATHOGENIC MECHANISMS THAT 
ARE DISTINCT FROM O1 VIBRIO CHOLERAE 
ABSTRACT 
Vibrio cholerae NRT36S is a non-cholera toxin (CT) producing, non-O1 V. 
cholerae strain that causes diarrhea in volunteers.  The genome of NRT36S was 
sequenced to a draft containing 174 contigs plus the superintegron region.  Our analysis 
of the draft genome revealed several putative toxin genes and colonization factors.  
Besides confirming the existence of nonagglutinable heat-stable toxin (NAG-ST), we 
also identified the genes for a type three secretion system, a putative exotoxin, and two 
different RTX toxin genes.  Four pili systems were also identified. 
STUDIES AND RESULTS 
V. cholerae is best known as the causative agent of cholera.  Cholera epidemics 
are associated with O1 and O139 serogroup isolates that produce cholera toxin (CT).  V. 
cholerae from the other more than 200 serogroups reported for this species may be 
isolated from sporadic small outbreaks and isolated cases of diarrhea.  The mechanisms 
by which these latter strains cause human disease remain controversial.  In this study, we 
sequenced the genome of a known pathogenic non-O1 V. cholerae clinical isolate and 
compared it to the fully sequenced genome of V. cholerae O1 El Tor N16961 (20-22).  V. 
cholerae NRT36S was originally isolated from a Japanese patient with travelers’ 
diarrhea.  It is serogroup O31, CT negative and produces NAG-ST (144).  When fed to 
volunteers this isolate caused diarrhea, including, in one patient, a 5.3-liter diarrhea purge 
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(41).  Molecular studies have indicated that this isolate is not closely related to epidemic 
O1 and O139 isolates (155). 
The V. cholerae NRT36S genome was sequenced by the company 454 Life 
Sciences.  Genomic DNA was extracted with a QIAamp DNA minikit (Qiagen, Valencia, 
CA).  454 Life Sciences employed a different sequencing strategy to the conventional 
shotgun sequencing.  The method is as described in (151).  Genomic DNA is randomly 
sheared to small fragments and ligated to common adaptors.  The fragments are then 
amplified by PCR and then sequenced.  Sequencing is performed on a Genome 
Sequencer 20TM System, which is based on pyrosequencing protocol.  The sequencing 
runs generated 1,082,967 reads and output 104,531,256 bp of sequence.  The estimated 
coverage depth was 26X.  The draft genome consisted of 174 large contigs plus the 
superintegron regions, with total length of 4,079,433 bp.  The average GC content for the 
draft genome was 47.5%.  The genome was annotated by the National Microbial 
Pathogen Data Resource and is available from the link:  (http://anno-
2.nmpdr.org/umd/FIG/index.cgi). 
We compared the genome of V. cholerae NRT36S to the published genome of V. 
cholerae N16961, of serogroup O1, using the program MUMMER 3.0 (settings of the 
program were as in default) (Figure 3.1) (156).  The genome sizes were comparable, at 
approximately 4.1 megabases.  About 3.5 megabases (89%) of the sequences were 
common to both genomes.  Substantial differences between the genomes of V. cholerae 
NRT36S and N16961 were noted, especially in the genes for pathogenesis, surface 
polysaccharides, and in the superintegrons.  The sequences identified in only one isolate 
by MUMMER (cutoff 70% nucleotide identity) were considered strain-specific. 
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We confirmed that the genes related to pathogenesis in V. cholerae N16961 were 
strain-specific.  These genes made up 30% of the N16961 specific sequences.  The 
CTX∅ prophage (VC1452-VC1478), which encodes CT in V. cholerae O1 (32), was 
absent from NRT36S.  The genome of CTX∅ also encodes genes responsible for the 
phage morphogenesis and its insertion into the host genome.  None of these genes were 
present in NRT36S.  The toxin co-regulated pilus (TCP), the major colonization factor 
for V. cholerae O1 (33, 34), was also missing from NRT36S.  TCP is encoded in a 39.5 
kb region of the V. cholerae genome, designated Vibrio pathogenic island 1 (Karaolis, 
1998).  Together with TCP, the genes encoded in Vibrio pathogenic island 1 (VC0819-
VC0845), including ToxR and other accessory colonization factors were absent from 
NRT36S.  Another genomic island was described as Vibrio pathogenic island 2 in V. 
cholerae O1 (VC1758-1803).  VC1759-1772 encode a restriction modification system; 
VC1773-1787 encode enzymes, including a neuraminidase, involve in the utilization of 
amino sugars (nan-nag region); VC1788-1803 encode phage proteins (Figure 3.2) (157).  
Neuraminidase was found to be an important virulent factor that can increase the human 
receptor for CT (158).  Most of the Vibrio pathogenic island 2 (VC1759-1772 and 
VC1788-1803) was absent from NRT36S.  But an internal section (VC1773-1787) the 
nan-nag region was present.  This interesting mosaic structure suggests that this region of 
the genome is a hot spot for lateral gene transfer. 
Two other genomic islands, named Vibrio seventh pandemic islands-I and II 
(VC0175-0185 and VC0490-0497) have been reported to be specific to V. cholerae O1 El 
Tor and related O139 strains (157).  The functions of these two islands are not clear.  
Neither of these islands was present in NRT36S. 
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The genes related to pathogenesis in NRT36S were different to N16961.  In a 
previous study (41), Morris et al. suggested that the heat stable enterotoxin NAG-ST and 
the ability to colonize were the major factors contributing to occurrence of disease in 
human volunteers ingesting NRT36S.  NAG-ST causes fluid accumulation in suckling 
mouse model (41, 144, 159).  NAG-ST was not present in N16961.  Interestingly, the 
NAG-ST gene was located to the superintegron region of the NRT36S genome (described 
below). 
The colonization factor(s) in NRT36S were not identified in the previous studies.  
We found four pili systems in NRT36S.  First, a type 1 pili assembly system was 
identified in an 8 kb sequence specific to the genome of NRT36S.  Second, a pili system 
in NRT36S related to a mating pili system in Salmonella typhi (160) was identified.  
Third, a type IV pili system, which was a mannose-sensitive hemagglutinin, described by 
Jonson et al. (161), was present in both NRT36S and N16961.  The protein sequences of 
the mannose-sensitive hemagglutinin system shared 60-99% identity between the two 
isolates.  Fourth, another type IV pili system, described previously (162), was also 
conserved in NRT36S and N16961.  None of the pili systems identified in NRT36S was 
similar to TCP, which is a type IV pilus. 
We also identified a type III secretion system (TTSS) in a 48 kb gene cluster 
specific to NRT36S.  It is highly similar to the one described for another non-O1/non-
O139 V. cholerae isolate AM-19226 (163), sharing 99% sequence similarity.  The 
location of the TTSS in NRT36S was next to the homolog of VC1758, while in N16961, 
the genes next to VC1758 were designated as Vibrio pathogenic island 2.  In NRT36S, 
we also found 2 additional potential toxin gene clusters that were not found in N16961.  
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The first was an exotoxin A precursor gene.  This gene had a homolog in the other non-
O1/non-O139 V. cholerae isolates AM-19226 (163) and V51 (164).  The predicted 
protein product is related to an NAD-dependent ADP-ribosyltransferase of Pseudomonas 
aeruginosa.  Second, there were two RTX toxin genes present in NRT36S.  The first one 
is similar to rtxA of N16961, sharing 99% amino acid identity.  The second RTX toxin 
gene is similar to the RTX toxin gene in Aeromonas salmonicida (E=0. Score=640) and 
was very divergent from the rtxA found in N16961. 
We identified two additional phage-like gene clusters in NRT36S.  One prophage-
like gene cluster was 33 kb and located adjacent to genes on chromosome II in N16961.  
The other cluster was 6 kb and showed similarity to filamentous bacteriophages KSF-
1phi and VGJphi.  Whether these two prophages play a role in virulence remains 
unknown.  Altogether, the putative virulence genes and phage sequences made up 33% of 
the strain-specific sequences in NRT36S. 
Besides the genes related to toxin and colonization, V. cholerae N16961 and 
NRT36S differed in their genes associated with synthesis of surface polysaccharide, 
which might also contribute to their virulence and survival.  These genes made up 9% 
and 13% of the strain-specific sequences, respectively, in N16961 and NRT36S.  The 
genes for O and K antigens in the two isolates were entirely different.  N16961 is 
serogroup O1 and has no capsule; its O antigen biogenesis region has been identified 
(48), occurring between gmhD and rjg in chromosome II.  NRT36S is serogroup O31 and 
has a capsule in addition to the O31 antigen.  The O-antigen and capsule shared the same 
genetic locus in NRT36S, also located between gmhD and rjg (Chen, Bystricky et al., 
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submitted for publication).  Nevertheless as expected, the gene contents of this locus in 
N16961 and NRT36S were very different.   
A superintegron exists in all the Vibrio genomes examined so far (20-22), and 
NRT36S was no exception.   The superintegron is a highly variable region.  The 454 
sequencing strategies generated only short reads that could not read through the Vibrio 
cholerae Repeats and gave problems for assembling the superintegron in NRT36S.  
Therefore our knowledge to the superintegron regions is not complete.  Among the genes 
we could confirm to the superintegron region, most of them were hypothetical proteins, 
as expected.  Several genes were homologous to the recognized genes in N16961 
superintegron:  a killer protein, 4 putative acetyl transferase and some hypothetical 
proteins were conserved in the superintegron of both NRT36S and N16961.  There were 
also several other genes recognized to be specific to the NRT36S superintegron.  As 
mentioned above, the superintegron encoded NAG-ST, which may be the major toxin of 
NRT36S.  We also identified a quinone oxidoreductase, and a hydrolase in the NRT36S 
superintegron. 
In addition to the genes for toxins, pilus, surface polysaccharide, and 
superintegron, the difference between N16961 and NRT36S extended to other genes in 
the other functional categories such as chemotaxis, transportation and metabolism, and 
transcription regulation.  These genes made up 32% and 24% of the strain-specific 
sequences in N16961 and NRT36S respectively.  A methyl accepting chemotaxis system 
in N16961 (VC0511-VC0515) was very divergent from its analogue in NRT36S and was 
identified by MUMMER as isolate specific.  The two systems shared about 30% amino 
acid identity.  A phosphenolpyruvate phosphotransferase system (PTS) was found in 
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N16961, which might be involved in the transport of chitobiose in V. cholerae (20).  This 
PTS system was unique to N16961 and was not found in NRT36S.  NRT36S had a 
unique ABC type oligopeptide transport system of 11 kb long.  It contained an outer 
membrane receptor gene, two genes of ATPase components, a periplasmic component 
gene and two genes of permease component.  There was also a 6 kb NRT36S specific 
sequence contained a lysine motif (LysM) repeat, it was next to the homolog of VC0018 
in NRT36S.  While in N16961, there are three hypothetical proteins (VCA0019-
VCA0021) specific to N16961 next to VC0018.  There were also 54 other genes unique 
to N16961 and about 20 recognizable proteins plus some hypothetical proteins specific to 
NRT36S; they were randomly distributed in the genome and were in clusters less than 
3kb. 
To gain insight of the variations between homologous genes in V. cholerae, we 
also compared the proteomes of the two isolates by BLASTP (settings for BLASTP: no 
filter, e value< 1e-10).  All best-hit pairs were identified from the two genomes.  Best-hit 
pair here was defined as one gene in one genome found the other in the other genome as 
its best match and vice versa.  Genes with 85% or more amino acid identity (AAI) and 
that cover at least 70% of the full length were considered conserved.  84% of the genes 
were conserved between the two genomes, less than 1% of the genes had low AAI 
(between 21% to 84%), another 1% of the genes represented paralogs in the genome, and 
the rest of the 14% of genes from NRT36S did not match N16961.  Genes that had less 
than 85% AAI were considered strain-specific. 
Our genome analysis reveals extensive variations among pathogenic strains 
within V. cholerae.  NRT36S and the O1 strain N169061 clearly have entirely different 
 70
sets of virulence-associated genes.  The observed variations in their surface 
polysaccharides and membrane transportation systems may reflect the adaptation to 
different niches during their life cycle.  The function of the superintegron remains 
cryptic.  NAG-ST is the first functional virulence gene found to be in the superintegron, 
which strongly suggests that the superintegron is a mechanism by which members of this 
species can import exogenous genes and convert them for their own adaptation. 
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Figure 3.1.  Comparison between V. cholerae genomes of N16961 and NRT36S.  The 
two close rings represent two chromosomes of N16961.  Chromosome I is on the left and 
chromosome II is on the right.  The white areas in the rings are sequences conserved 
between the two genomes.  Red areas are sequences specific to N16961, with labels 
inside the rings.  Blue areas outside the rings are sequences specific to NRT36S, with 




Figure 3.2.  Mosaic pattern of Vibrio pathogenic island 2.  The three regions in the Vibrio 
pathogenic island were described in (157).  White boxes are conserved regions between 
N16961 and NRT36S.  Shades boxes indicates genes specific to N16961.  Box with stripe 
pattern indicates genes specific to NRT36S.
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CHAPTER IV: GENETIC VARIATION OF 
CAPSULE/LIPOPOLYSACCHARIDE BIOGENESIS IN TWO SEROGROUP O31 
VIBRIO CHOLERAE ISOLATES 
ABSTRACT 
NRT36S and A5 are both NAG-ST producing, serogroup O31 Vibrio cholerae.  
NRT36S is encapsulated and causes diarrhea when administered to volunteers; A5 is 
acapsular and does not colonize or cause illness in humans.  The 
Capsule/Lipopolysaccharide (CPS/LPS) biogenesis regions in these two isolates were 
similar except that a 6.5 kb fragment in A5 replaced a 10 kb fragment in NRT36S in the 
middle of the LPS gene cluster.  Our data highlight the apparent mobility within the 
CPS/LPS region that would provide a basis for the large number of observed V. cholerae 
serogroups and the emergence of novel epidemic strains.  
STUDIES AND RESULTS 
Vibrio cholerae has nearly 200 serogroups based on the O antigen (14).  Antibodies 
specific for O1 and O139 antigens are critical for protective immunity against cholera.  
Most non-O1 serogroup isolates also have a capsule that is critical for virulence in 
extraintestinal infections (50, 73).  The biogenesis of these polysaccharides in V. cholerae 
is not well understood.  Although O1 is the predominant serogroup that causes pandemic 
cholera, new strains with epidemic potential continue to emerge by acquiring new O 
antigens and capsule polysaccharides.  Understanding the genetic basis underlying the 
generation of new O antigens and capsules is critical for developing insight into the 
evolution of V. cholerae, and may influence the strategy for vaccine development.   
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The O antigen biogenesis regions of five V. cholerae isolates from different 
serogroups (O1, O22, O31, O37 & O139) have been resolved (15, 16, 18, 27, 47, 49, 
166), all flanked by the genes gmhD and rjg.  In serogroup O139 isolates, both the O 
antigen and the capsular polysaccharide (CPS) are constructed of the same subunit that is 
encoded in a single region.  In the O31 V. cholerae strain NRT36S (isolated from a 
Japanese patient with travelers diarrhea (41, 159)), the CPS and O antigen share the same 
biogenesis region, which consists of 46 genes (166).  Although there are immunologic 
differences in the CPS and the LPS, there is no immediately obvious organizational 
differentiation between the genes specific for CPS versus O antigen biosynthesis.  
V. cholerae A5 (cultured from frozen shrimp (144)) is a naturally-occurring 
acapsular isolate closely related to NRT36S, as shown by genetic studies (155).  In a 
multi locus sequencing typing (MLST) study, the two strains were identical for seven 
sequenced housekeeping genes, cat, chi, dnaE, gyrB, lap, recA, and pgm (unpublished 
data).  They have the same serogroup, O31, and both produce NAG-ST (144, 159).  
However, a volunteer study showed that A5 failed to colonize and did not cause disease 
while NRT36S colonized volunteers and produced severe diarrhea (41).  Given that both 
strains are toxigenic (producing NAG-ST, a well-recognized diarrheal toxin), it is 
reasonable to hypothesize that the difference in pathogenicity is a function of colonizing 
ability; this, in turn, may be related to capsule status.  To assess the genetic basis for this 
difference, we sequenced the O antigen/capsule biosynthesis region of A5, and compared 
it with the previously reported sequence of NRT36S. 
Origin of the A5 polysaccharide genes:  Since both NRT36S and A5 are in 
serogroup O31, we anticipated that their O-antigen genes would be very similar and that 
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CPS gene(s) might have been deleted or mutated in A5.   We designed primers to amplify 
different regions of the CPS/LPS gene cluster in NRT36S and A5, with the total outcome 
spanning the entire cluster from gmhD to rjg. The same size PCR products were 
amplified from NRT36S and A5 from all regions except one.  Primers 1197 
(TGAGCAATCCGGTATTGAAGTGAAA) and 1528 
(AGGTTATCGTACAGTGCTTT) amplified a fragement of ~7 kb from A5 in contrast to 
a ~11 kb fragment from NRT36S.  The PCR products amplified with primers 1197 and 
1528 were sequenced (GenBank accession number EF076669).  Open reading frames 
were annotated using the program Artemis (154) and putative function was assigned by 
similarity searching against GenBank with the program BlastP (152, 167).  Sequence 
analysis from this region indicated that a 6.4 kb DNA sequence in A5 had replaced a 10.5 
kb region in NRT36S, with breakpoints in the genes wzc and ugd (Figure 4.1A, 1B and 
1C) suggesting a single mutational event.  The 10.5 kb region specific for NRT36S 
encoded 11 genes, including a set of the 4 rhamnose pathway (rmlBADC) genes, a 
flippase (wzx), two O-acetyl transferase, a putative wzy gene, two glycosyltransferases, 
and a putative rhamnosyltransferase (orf43) (Figure 4.1A, Table 4.1).   
The A5 specific sequences in the LPS region encoded six genes (Figure 4.1A, Table 
4.1), including a wzx (O antigen flippase), a wzy (O antigen polymerase), an O-acetyl 
transferase (orf D), and three putative glycosyltransferases (orfs B, E and F).  Between 
the genes specific for A5 and the ones specific for NRT36S, wzx was the only gene that 
had significant similarity to its counter part in the other isolate, sharing 28% amino acid 
identity (E=4e-35).    Although there was little similarity between the strain specific 
regions from A5 and NRT36S, there was a striking similarity in the organization (Table 
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4.1).  The unique region from each isolate consisted of a wzx homologue, 
glycosyltransferase, putative wzy homologue, acetyltransferase, and two 
glycosyltransferases in the same order in both isolates.  The rhamnose genes in the 
NRT36S specific region are duplicates with rmlA-D genes occurring in ORFs 1-4 in 
NRT36S. 
Sufficient genes to synthesize O antigens that react with O31 typing sera are clearly 
present in the regions shared by NRT36S and A5.  It is possible that the A5 specific 
genes may be able to substitute for the NRT36S genes they replace in O antigen 
biogenesis, or that the exchange of genes corresponds to a change in the O antigen 
structure that is not reflected by the specificity of the typing sera. 
The region in NRT36S replaced in A5 contains at least part of the genes necessary 
to encode capsule biogenesis.    In a previous study of NRT36S, orf43 was disrupted in 
two independent transposon mutagenesis experiments, and the disruption resulted in the 
loss of the capsule in NRT36S (166).  The gene orf43 was among the ones replaced in the 
acapsular A5. 
As noted above, the genes gmhD and rjg appear to form a cassette-like element 
containing the genes necessary for O antigen/CPS biogenesis.  The emergence of V. 
cholerae O139 is consistent with homologous exchange within these flanking genes (15, 
47, 48).  Within this larger cassette, the region divergent between NRT36S and A5 was 
flanked by two genes, wzc and ugd, consistent with formation of a “sub-cassette” capable 
of undergoing lateral gene transfer.  Interestingly, this substitution did not result in a 
change in O antigen or capsule type, but rather the loss of capsule expression.  This 
contrasts with observations made with the polysaccharide biogenesis genes of V. cholerae 
 77
O139 and O22; these biosynthesis regions are very similar, but have a small region that 
differs, resulting in a change in serogroup.  It is less clear that a single exchange could 
result in the differences between O139 and O22 strains, and  it has been suggested that 
insertion elements were involved in the gene rearrangement in these two strains (49).   
GC percentage pattern:  Our results are consistent with the idea that there is a 
constant “mixing and matching” of different sub-cassettes within the O antigen/CPS 
biosynthesis region, providing a basis for the large number of observed V. cholerae 
serogroups.  To further explore this concept, we examined the patterns of GC content in 
the O antigen/CPS region of V. cholerae.  GC percentage plots were generated using a 
120 bp widow size with the program Artemis (154).  The O antigen/CPS of NRT36S 
displayed five distinct regions, with dramatically changes of GC content among regions 
(Figure 4.2). In region I, III, V, the GC contents were (46-47%), close to the GC content 
of the chromosomal backbone (48%).  Region II and IV had lower GC content, 36% and 
31% respectively, suggested these two regions were acquired recently.  In A5, region IV 
was replaced by the A5 specific sequence and GC content of the new sequence was 29%.  
Interestingly, all genes in region I, III, V of NRT36S had homologs in Vibrio, suggesting 
these genes were acquired by the ancestral V. cholerae.  In contrast, none of the genes in 
region II and IV had homologs in Vibrio in the current database (166).  This observation 
was consistent with the GC patterns, and strongly suggested that there were at least two 
recombination events recently in the CPS region of NRT36S, acquiring region II and 
region IV respectively.   
We also examined the GC pattern in the O antigen/CPS cluster in Vibrio cholerae 
O139 and O22.  There were three distinguishable regions in either O139 or O22, and 
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region II had low GC content (32% and 31%, Figure 4.2).  This region was found to be 
the only region to diverge significantly from O139 to O22 (49).  The case of O139 and 
O22 appears to be very similar to that of NRT36S and A5, supporting the concept that 
homologous exchanges between sub-cassettes in the polysaccharide region alter the 
structure of the surface polysaccharide.  Secondly, the %GC differences suggest that this 
exchange may involve acquisition of genes from other species. 
Phylogeny:  We noticed that GC content changed abruptly between different regions 
in the CPS/LPS region, as described above.  Furthermore, genes in the region with low 
GC content did not have homologs in Vibrio.  This suggested that original source of these 
low GC content regions might be outside of Vibrionacea.  To further investigate that 
idea, we examined the phylogeny of housekkeping genes and compare it to two 
conserved polysaccharide genes within V. cholerae, ugd and galE.  If there were 
extensive recombination within polysaccharide biosynthetic regions, one would expect 
the evolution of polysaccharide biosynthesis genes to follow an evolutionary tree that 
includes multiple independent branches compared to genes from genetic backbone where 
the tree will have single branch for V. cholerae.  Homologous genes of galE, ugd, were 
retrieved from GenBank.  The protein sequences were aligned with ClustalX (168) and 
the genetic trees were constructed with Treeview (169).  Besides O31, Ugd was also 
present in V. cholerae serogroups O22, O139, O141 and in many other species of gram-
negative bacteria.  An unrooted tree (Figure 4.3) was constructed using the protein 
sequences of ugd genes.  Within the cluster of Vibrionacea, the Ugd sequences of V. 
cholerae O139, O22 and O141 were closely related and clustered together (cluster A), 
while those of ugd from the O31 isolates (A5 and NRT36S) were far away from cluster 
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A.  The Ugd of O31 and O139 shared 80% Amino Acid Identity (AAI).  The distance 
from the O31 to cluster A was further than the distance of many other Vibrio sp. (other 
than V. cholerae) to cluster A, suggesting there were two different evolution lineages of 
ugd gene in V. cholerae. 
galE was present in many V. cholerae strains.  An unrooted tree was constructed 
based on their protein sequences (Figure 4.3).  Similar to Ugd, V. cholerae separated into 
two clusters in the GalE tree (C and D in Figure 4.3), Cluster C consisted of V. cholerae 
O1 (El Tor and classical strain 0395), O37 (1322-69 and V52), O31 (NRT36S and A5), 
cluster D consisted of O139 (MO10 and AI1837) and O22.  The AAI between the two 
clusters were about 50%, while the AAIs were 98-99% inside clusters.  These results 
strongly suggest that there are different ancestral galE genes for V. cholerae. 
Our analysis from the conserved polysaccharide biogenesis genes indicated that 
there were at least two evolutionary lineages of V. cholerae polysaccharide genes.  
Opposite to the evolution lineages of the genetic backbone, O1 and O139 were separated 
in two evolution lineages for the polysaccharide genes, each together with different 
serogroups of non-O1, non-O139 strains.  In the evolution of polysaccharide genes, O1 
was close to O31 and O37, while O139 was close to O22 and O141.  There are many 
other species intervening between the two V. cholerae lineages, supporting our 
conclusion that homologous exchange between different species contributed to the vast 
variation in V. cholerae surface polysaccharides. 
The polysaccharide biogenesis region is one of the most variable regions in the 
genome and lateral gene transfer has played an important role in its evolution.  As a 
result, the serogroups in V. cholerae do not necessarily follow the evolution of its 
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chromosomal backbone, as reflected in phylogenetic trees constructed in other studies 
(23).  For housekeeping genes such as those used for MLST, all of the genes are very 
closely related, indicate that vast majority of housekeeping genes have a single lineage or 
phylogenetic branch for V. cholerae (23, 25, 155).  In contrast, gmd, a gene for O-antigen 
biogenesis in V. cholerae O139, has an allele that has greater similarity to E. coli than to 
Vibrio, suggests lateral gene transfer (25). The evolution of the CPS/LPS region hence 
seems to follow its own path, different from the lineage of the chromosomal backbone, 
with the frequent occurrence of lateral gene transfer, often across species boundaries.  
From our study, we found that genes switch from NRT36S to A5 were strikingly similar 
in three ways: a) same type of genes, both related to polysaccharide biogenesis; b) similar 
organization; c) similar GC pattern.  All these evidences suggest that there is a controlled 
mechanism for the recognition of and recombination in the LPS/CPS region leading to 
increased mobility of genes in this region, and the surface polysaccharides of V. cholerae 
are highly plastic.  The inclusion of LPS/CPS genes from other species into the pool 
greatly increases the chance for the emergence of new epidemic strains of V. cholerae.  
As a result, novel epidemic strains with new serogroups and CPS structures will continue 





















Figure 4.1.  Divergent regions in CPS/LPS of NRT36S and A5.  Arrows indicate the 
breakpoints. A. NRT36S specific region have 11 genes.  A5 specific region have 6 
different genes.  The two regions are flanked by two conserved genes wzc and ugd.  B.  




Table 4.1.  Strain specific genes. 
NRT36S A5 
O antigen translocase wzx  
(Pelodictyon luteolum 30%) 
O antigen translocase wzx  
(Pelodictyon luteolum 32%) 
Glucosyltransferase  
(Pseudoalteromonas tunicate 34%) 
Glycosyltransferase  
(Methanosphaera stadtmanae 29%) 
Predicted saccharide polymerase wzy Putative saccharide polymerase wzy  
(Shewanella  oneidensis 23%) 
Sugar acetyltransfease 
(Cytophage hutchinsonii 51%) 
O-actetyl transferase 
(Clostridium acetobutylicum 26%) 
Glycosyltransferase 
(Cytophaga hutchinsonii 29%) 
Glycosyltransferase 
(E. coli 39%) 
Rhamnosyltransfease 
(Shewanella sp. 66%) 
Glycosyltransferase 




Figure 4.2. GC content of O antigen/CPS clusters in V. cholerae.  Average GC content of 
each region is indicated under each plot.  The numbers on the right are the range of GC 
content in percentage. The grey line of each plot indicated the average GC content of the 
entire cluster.  Grey filled bar indicates the divergent region between NRT36S and A5.  
Black filled bars indicate the divergent regions between O139 and O1. 
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Figure 4.3.  Unrooted protein trees of Ugd (left) and GalE (right).  The length of branch is 
proportional to the genetic distance.  Ugd of V. cholerae separate into two clusters (A and 
B).  GalE of V. cholerae also sepatate into two clusters (C and D).  
 85
 
CHAPTER V:  DETAILED EXPERIMENTAL METHODS 
Culture conditions 
Cultures were maintained in L broth with 15% glycerol at -70°C.  Bacteria were 
cultured in the L broth or agar at 37°C unless otherwise stated.  Appropriate antibiotics 
were added in concentrations: 50 mg/ml Kanamycin, 50 unit/μl polymycin B.  To 
visualize the opacity of colonies, bacteria were grown on L agar containing 10g/L NaCl.  
A beaker of water was put inside the incubator to keep humility.  I found these growing 
conditions produce better differentiation between opaque and translucent morphology. 
 
Transposon mutagenesis 
Conjugations were performed between V. cholerae NRT36S as the recipient strain 
and E. coli S17λpir/putKm2 as the donor strain.  Ten μl overnight culture of V. cholerae 
NRT36S was spotted on LB agar and let dry, 10 μl overnight culture of S17λpir/putKm2 
was then spotted on top.  After overnight incubation at room temperature, the mixture 
was re-suspended in 1 ml of LB broth; 50 μl of the suspension was plated onto LB agar 
with kanamycin and polymycin B to select for V. cholerae mutants.   
  
Analysis of DNA in NRT36S mutants 
DNA flanking the transposon in the mutants was amplified and sequenced by a 
modified inverse polymerase chain reaction (PCR) protocol (147).  Genomic DNA was 
isolated with PrepManTM (Applied Biosystems) according to the manufacturer’s 
instruction.  A small amount of bacteria grown on LB agar was picked into 100 μl of 
PrepManTM sample buffer, dispersed by gentle pipetting, boiled for 15 min.  The samples 
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were cooled down and spun for 15 min.  The supernatant was transferred to a fresh tube 
and ready for downstream application.  Two μl genomic DNA of the above preparation 
was digested with 5 units of Nla III (New England Biolab) in a 20 μl reaction overnight 
followed by denaturing at 65°C for 15 minutes.  Two μl of the digested DNA was self-
ligated with 5 units of T4 DNA ligase (Invitrogen) in a 10 μl reaction.  One micro liter of 
this solution was used as PCR template.  Two primers were designed to anneal to the 
transposon mini-Km2, pointing outwards to amplify the flanking sequence of the mutant 
genomic DNA.  The sequences of the primers are, L8 (reverse), 
GTACCGAGCTCGAATTCGGCCTAG; and L9 (forward), 
GGAGAAAACTCACCGAGGCAGTTC.  PCR was performed in a 30 μl reaction 
containing 100 μM of each dNTP, 1.5 mM of MgCl2, 1x PCR buffer (Invitrogen) and 1 
unit of Taq DNA polymerase (Invitrogen).  We used a PE9700 thermo cycler (Applied 
Biosystems) with the following program:  An initial denaturing at 95ºC for 2min, 
followed by 35 cycles of: 95ºC for 30 second, 62ºC for 30 second, and 72ºC for 2min.  
PCR reaction was kept at 4ºC.  PCR products were purified with the Multiscreen PCR 
plates (Millipore) and sequenced using the BigDye® Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems).  The resulting fragments were separated and recorded in an 
ABI 3730x1 automatic sequencer (Applied Biosystems).  DNA sequence was then 
analyzed by the PHRED and PHRAP software (148-150). 
 
Serum Killing 
Translucent colonies were challenged with complement in human serum as 
previously described (50).  Thirty six μl of guinea pig compliment (Sigma) was added to 
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1 ml of pooled human serum to make serum mixture.  Thirty five μl of bacteria culture, 
containing 0.5x107 cells was mixed with 65 μl of serum mixture and incubated at 37ºC 
for 1 hour.  Control aliquots were mixed with serum that had been heated to 56ºC for 30 
min.  Two concentrations, either 5 or 45 μl of this mixture were plated on L agar.   
 
Size Exclusion Chromatography (SEC) 
Capsule preps were analyzed by SEC using a Beckman Coulter 32 Karat HPLC, 
with TSK gel column (JOSOHAAS; G3000SWxL; 10um; 30cmx7.5mm), and detected at 
200nm wavelength.  Purified NRT36S capsule was the same sample that was used for 
NMR.  Capsule preps were prepared as following: The amount of 109 cells were 
harvested into 0.5X PBS and shaken for 2 hours in a rotary shaker at 250rpm followed by 
centrifuge at 12000g for 20min.  The supernatant was treated with 20 μl proteinase K 
(Qiagen).  The supernatant was then extracted with phenol-chloroform and precipitated 
with ethanol.  The pellet was re-suspended in water and 1/3 of the amount was loaded.   
 
Immuno Blotting 
Immuno blotting was performed as described (47).  Circa 5x106 bacterial cells were 
washed with 0.5X PBS and treated with proteinase K (Qiagen).  Washed whole cell in 
PBS was mixed with 2X sample buffer and boiled for 5 min and was loaded on 16% 
SDS-polyacrylamide gel.  The samples were separated for 1.5 hours at 150 volt in an 
Xcell II electrophoresis apparatus (Invitrogen).  Samples were transferred to an Immuno-
Blot PVDF membrane (BioRad, Hercules, CA) for 2 hours at 25 volt in an Xcell II 
transfer module.  Blots were blocked in PBS contains 3% non-fat dry milk and then 
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incubated for 1h in 1:1000 rabbit antiserum specific for V. cholerae NRT36S.  The blots 
were washed three times with PBS and incubated with alkaline phosphatase-conjugated 
goat anti-rabbit immunoglobin G (Sigma) at 1:10,000 in PBS for 1h.  The blot was 
washed five times with PBS and developed with Western Blue colorimetric detection 
solution (Promega). 
 
Transformation of V. cholerae by electroporation 
V. cholerae was grown to log phase.  The following steps were all performed at 4ºC.  
Twenty ml of culture was centrifuged for 2 min at 1000g; Pellets were washed twice with 
10 ml of 137 mM sucrose pre-chilled to 4ºC, and re-suspended in 400 μl of 137 mM 
sucrose with 10% glycerol.  The cells were aliquot into 100 μl each. 
One μg plasmid DNA in 10 μl water was mixed with one aliquot of competent cells; 
chilled on ice for 15 min and transferred to a 0.2 cm Gene Pulsar cuvette (Biorad).  
Electroportation was performed in a Gene Pulsar Xcell electroporator (Biorad) with 
settings: 25 uF capacity, 2500 volt and 200 Ω.  Cells were immediately transferred to 1 
ml of SOC medium pre-warmed to 37ºC, and shaken for 1 hour at 37ºC.  Fifty to 100 μl 
of culture was plated L agar with appropriate antibiotics. 
 
Complementation of translucent mutant Tr3 
A DNA fragment containing genes galE, wbeW and their promoter was amplified 
from the genomic DNA of NRT36S by PCR.  Primers used are Stine1454: 
TGTCTAGAATTGCTTAGCAGCTCGCCTT, and Stine 1455: 
TTCTCGAGAATCCGAACCGCATCTGGAT.  PCR was performed in a 30 μl reaction 
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containing 20 ng template DNA, 100 μM of each dNTP, 20 picomole of primers, 1.5 mM 
of MgCl2, 1x PCR buffer and 1 unit of TaqGoldTM DNA polymerase (Applied 
Biosystems).  The PCR program of thermal cycler was: Initial denaturing at 95ºC for 30 
sec, followed by 30 cycles of 95ºC for 30 second, 55ºC for 30 second, and 72ºC for 1 
min. 
The PCR fragment was inserted into vector PCR2.1 using TA cloning kit 
(Invitrogen) and transformed into Top10 E. coli cells (Invitrogen).  The plasmid 
constructed, i. e. galE and wbeW in PCR2.1 was named pYS101.  The galE gene and its 
promoter were excised from pYS101 by restriction enzymes Hind III and Xho I; inserted 
into plasmid pACYC184, which was linearized by Hind III and Sal I.  The resulted 
plasmid was named pYS104 and multiplied in E. coli OmniMAX (invitrogen).  pYS104 
was isolated and introduced into competent cells of Tr3 by electroporation (described 
previously).   
 
Amplification of the LPS region in A5:  
We designed primers to amplify different regions of the CPS/LPS gene cluster in 
NRT36S and A5, with the total outcome spanning the entire cluster from gmhD to rjg.  
The same size PCR products were amplified from NRT36S and A5 from all regions 
except one.  Primers are listed in table 5.1.  Unless stated otherwise, PCR conditions are 
as follow: 94ºC for 1min, followed by 35 cycles of 94ºC 30 sec, 55 ºC or 50ºC 30 sec and 
72ºC 4 min.  The elongation time for primer pair 10 is 1 in.  Primers 1197 and 1528 
amplified a fragment of ~7 kb from A5 in contrast to a ~11 kb fragment from NRT36S.  
PCR with primers 1528 and 1197 was performed with GeneAmp XL PCR kit (Applied 
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Biosystems) following the manufacture’s instruction.  The long range PCR program of 
thermal cycler was: 94ºC for 1min, followed by 30 cycles of 94ºC 15 sec, 55 ºC 30 sec 




Table 5.1 Primers to amplify the CPS/LPS region of NRT36S and A5. LR PCR, long 




NRT36S CPS Sequence Condition 
1 J101 F >1 (gmhD) 
GCCATCCCACTCTGTGGTCGCA 
GAGCAAGCTCC LR PCR 
  1383 R 9584 (orf 8) TAGAGTATTCATCATTCCCC   
2 J101 F >1 (gmhD) 
GCCATCCCACTCTGTGGTCGCAGA
GCAAGCTCC 55°C 
  1150 R 4526 (rmlC 1) TGTCCGATAATAATAGCCCTTCCG   
3 1149 F 4920 (wzm) 
CCATTAGAGATACTTCCTGTGGTA
G 55°C 
  1385 R 8097 (orf 7) TCATTTCCGTCAATGTAGCA   
4 1384 F 9092 (orf 8) ACTAACTTCAATATTGAGAGAG 55°C 
  1541 R 13125 (orf10) CTGTTAAACCAGCAGCACAATA   
5 1540 F 13105 (orf 10) TATTGTGCTGCTGGTTTAACAG 50°C 
  1543 R 17146 (orf 16) AACAGCAAAAGCAAACACAGGGA   
6 1542 F 17122 (orf 16) TCCCTGTGTTTGCTTTTGCTGTT 50°C 
  1410 R 21552 (orf 22) GGAACTTGATGTATGCTGTC   
7 1411 F 20950 (orf 21) CCGCCCATTCAATTCTGATT 55°C 
  1381 R 24596 (wbeW) CTTACCGACTCGCTGTTGGC   
8 
1382 
F* 24063 (galE) GATTCCCTTACCTCTTGGTGC LR PCR 
  J103 R 48630 (rjg) 
CCCGTGACACTCGCCTTCCCTCCGT
GATGAACC   
9 1197 F 34660 (wzc) 
TGAGCAATCCGGTATTGAAGTGAA
A LR PCR 
  1528 R 45712 (ugd) AGGTTATCGTACAGTGCTTT   
10 1547 R A5 (wzy) AGTGAGTTTATTGTAAGATTTAG 55°C 
  1549 F A5 (orf C) CATTAAAGTAAGCAACACGCA   
11 1190 F 34730 (wzc) GCTATTACAACTACAGCTATGGTG LR PCR 
  J103 R 48630 (rjg) 
CCCGTGACACTCGCCTTCCCTCCGT
GATGAACC   
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CHAPTER VI: CONCLUSIONS AND FUTURE PROSPECTS 
SUMMARY 
My first hypothesis was that there was a distinct region for the capsule biogenesis, 
different from the lipopolysaccharide (LPS) biogenesis region.  I have identified the LPS 
region in the NRT36S genome based on our understanding of the conserved genetic 
structure of the LPS in V. cholerae.  I also identified the genes for capsule biogenesis by 
constructing transposon mutants of V. cholerae NRT36S.  Transposons mapped to the 
LPS region resulted in the loss of CPS, suggesting that it was a single region for both 
LPS and CPS biogenesis.  When the entire genomic sequence of NRT36S was examined, 
only two polysaccharide biogenesis regions were identified, one is as the 
exopolysaccharide (rugose) biogenesis gene cluster (VC0917-VC0939), and the other 
was the LPS/CPS region.  The lack of a third polysaccharide region supported the sharing 
of LPS and CPS genes.  Therefore, in contrast to my original hypothesis, I concluded that 
the capsule genes were embedded among the O-antigen gene region.  Although this is 
similar to the case in O139, there are significant differences.  The capsule polysaccharide 
in O139 shares the same repeating unit as the O-antigen and the O-antigen has only one 
single repeating unit attached to the core.  Although we have not determined the structure 
of the O-antigen in NRT36S, there are several lines of evidence suggesting that the 
capsule and O-antigen are two different entities in this strain.  First, the capsule was 
unable to react to the antibodies raised against the whole cell, while the O-antigen did; 
second, the capsule contains rhamnose, while other studies suggested the O-antigen of 
this serogroup did not have rhamnose (142); third, the natural mutant A5 lost the capsule 
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yet retained its O-antigen suggesting that some genes required for capsule biogenesis are 
not needed for LPS formation.   
In contrast to my original hypothesis, I drew our final conclusion that the capsule 
and LPS biogenesis region were combined in at least some strains of V. cholerae.  This 
finding was novel and significantly different from E. coli.  In all four groups of E. coli, 
there are different gene clusters for the capsule and O antigen.  The integration of CPS 
and O-antigen genes, and the fact that they are flanked by two conserved homologous 
genes, suggests that V. cholerae can readily change its capsule and O-antigen 
simultaneously, just like changing its camouflage, yet maintaining its other virulence 
factors in the genome.  This finding has important implications in vaccine development 
since the O antigen is the major protective antigen.  Vaccine strains should also be 
acapsular since encapsulated V. cholerae can evade phagocytosis and become invasive, 
and cause septicemia in the immuno-compromised patients. 
To further investigate the genetic basis underlying the generation of new O 
antigen/CPS, I compared the CPS/O-antigen biogenesis regions in two natural V. 
cholerae variants (A5 and NRT36S), with the same O serogroup.  I found direct evidence 
that homologous exchange of part of the polysaccharide biogenesis region caused the 
variation in the surface polysaccharide structures.  V. cholerae A5 replaced some of the 
CPS/O-antigen biogenesis genes of NRT36S with other new genes.  Consequently, A5 
lost the CPS but retained the same O-antigen as NRT36S.  This evidence supported the 
hypothesis that lateral gene transfer by homologous recombination played an important 
role in the evolution of polysaccharide genes, and hence of V. cholerae.   
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The O antigen/CPS region in V. cholerae is flanked by two homologous genes 
gmhD and rjg.  And inside this region, there are different genes conserved among 
different serogroups and can serve as the basis for homologous recombination.  The 
genetic structure of O antigen/CPS in V. cholerae suggests that this region not only can 
undergo homologous recombination as one unit, but also can exchange its component 
sections as sub-cassettes.  The concept of recombination between sub-cassettes is 
supported by the GC patterns of the O antigen/CPS regions.  GC percentage changes 
abruptly between different sub-cassettes.  The most variable sub-cassettes in NRT36S 
and A5, and in O139 and O22 have much lower GC content compared to their genetic 
backbone, suggesting recent acquisition by lateral gene transfer.   
Examination of the phylogeny of the conserved genes in the O antigen/CPS of V. 
cholerae revealed that lateral gene transfer in this region not only involved the same 
species, but also involved different species, and even different genera.  Therefore, the 
large gene pool plus the greatly increased mobility in the O antigen/CPS region may 
contribute to the large number of serogroups observed in V. cholerae.  Furthermore, 
emergence of novel strains is expected to continue. 
My study supports my second hypothesis that horizontal gene transfer plays a 
critical role in the evolution of V. cholerae, especially in generating the diversity of 
surface polysaccharides.  Lateral gene transfer contributes to the emergence of new 
strains by acquiring new polysaccharide genes as well as virulence genes.  In turn, it 
makes the genome of V. cholerae dynamic.  I studied the genome of V. cholerae 
NRT36S, as discussed in chapter 3.  This was the first study to directly compare two 
genomes of V. cholerae.  This study gave a direct evidence of the types and extent of 
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variation in the genome of V. cholerae.  Eleven percent of the sequences were specific to 
the specific V. cholerae genomes.  Many of those sequences appeared as genomic islands 
that may have arisen from lateral gene transfer.  Insertion of bacteria phage and 
homologous recombination may be major mechanisms of the lateral gene transfer 
responsible for the rise of the genomic islands.   
Lateral gene transfer has resulted in two entirely different pathogenesis mechanisms 
in the epidemic and NAG-ST pathogenic V. cholerae.  In epidemic V. cholerae, the major 
virulence factors are CT and TCP.  CT and TCP, as well as other genes related to 
pathogenesis, including VPI-1, VPI-II, VSP-1 and VSP-II are in different gene clusters 
present specifically in epidemic strains and were not found in NRT36S.   In contrast, 
NRT36S possessed multiple different potential virulence factors, at different locations in 
the genome.  NAG-ST has been shown to be an important toxin in non-O1 V. cholerae 
(41, 144).  We located the NAG-ST gene in the super-integron region (SI).   This is the 
first functional virulence gene identified to the SI, strongly suggests the role of SI in 
acquiring exogenous genes.  In addition to NAG-ST, we identified a type III secretion 
system, which could be a potential virulence factor.  There are several other potential 
toxins, including an exotoxin A and two RTX toxins.  One of the RTX toxins is present 
in both the epidemic strain and NRT36S, while the other is specific to NRT36S.  The role 
of these potential toxins remains to be investigated.  In NRT36S, I also identified 4 pili 
systems as potential colonization factors.  A type 1 pilus and a mating pilus are present 
only in NRT36S; two type IV pili were conserved in both the epidemic strain and 
NRT36S.  Altogether, these potential toxins and colonization factors suggest the 
pathogenic mechanism in non-O1 V. cholerae is distinct from that of the epidemic 
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strains.  My analysis of the genome of NRT36S has advanced our understanding of 
pathogenic mechanism of non-O1 V. cholerae. 
My analysis suggests that phages were tightly linked to pathogenesis.  Most of the 
virulence genes specific to O1 N16961 were closely related to phage.  In NRT36S, phage 
related genes and sequences made up 25% of its genome specific genes.  None of the 
virulence factors found in the epidemic O1 and O139 strains was present in the O31 
pathogenic strain NRT36S.  Instead, I have identified new putative virulence factors in 
non-O1 V. cholerae.  Both pathogenic V. cholerae, O1 El Tor and O31 NRT36S, share 
many biochemical and genetic properties, and both have multiple virulence factors, but 
surprisingly almost none of the virulence factors overlap.  This suggests that the ancestral 
strain of V. cholerae was an environmental organism and that toxigenic strains arose from 
multiple independent acquisitions of virulence factors through horizontal gene transfer 
events. 
In summary, studies presented in my dissertation have extended our knowledge in 
understanding the evolution of V. cholerae.  The genome of V. cholerae is dynamic.  It 
may acquire new pathogenic features, antigens and capsules by lateral gene transfer.  As 
we showed with NRT36S and A5 and has been shown for O1 El Tor, O139 and O37, a 
virulent strain may acquire genes for a new or modified polysaccharide antigen in a 
single simple recombination event and become a new serogroup capable of causing 
disease even in those exposed to another toxigenic strain of V. cholerae.  Lateral gene 
transfer has played a critical role in maintaining the polysaccharide diversity, as well as 
acquiring virulence factors, and hence the emergence of new epidemic strains.  I would 
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expect novel epidemic strains, with a similar toxigenic background to the current ones, 
but different serogroups, continues to emerge. 
 
CONCLUDING REMARKS AND FUTURE PROSPECTS 
Lateral gene transfer plays a critical role in the evolution of V. cholerae and 
eventually leads this species to pathogenesis.  My preliminary analysis of the 
pathogenesis genes provides new clues and directions for the future study into 
pathogenesis.  By examining the genome of NRT36S, I identified several potential 
virulence factors, which might be critical in the pathogenic mechanism for non-O1 V. 
cholerae.  Among them, NAG-ST was suggested to be an important toxin (41).  But 
others were not described before for NRT36S.  A TTSS system, an exotoxin A gene, and 
a RTX toxin were found.  These could be important virulence factors, but functional 
studies will need to be done in order to be conclusive.  Several pili systems were also 
identified which could be important for colonization of the human host.  Although 
colonization was found to be required for the pathogenesis of NRT36S, no pilus genes 
were identified previously (41).  To confirm a role of these pili in pathogenesis, 
functional studies including specific gene knockouts and animal models are required. 
Bacteria often employ similar strategies for polysaccharide biogenesis.  From the 
genes present in the capsule biogenesis region in V. cholerae NRT36S, I speculate that 
the capsule synthesis pathway in V. cholerae is similar to group 1 E. coli, although there 
are also significant differences.  Capsule biogenesis in E. coli depends on either wzx/wzy 
in conjugation with wza, wzb, wzc pathway or wzm/wzt pathway.  All of these genes are 
present in the capsule/LPS region of NRT36S, consistent with V. cholerae using similar 
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mechanism for capsule exportation.  However, never there has been a case reported in the 
other species that all 7 of capsule exportation genes are present in a single isolate and 
some of these genes may not be involved in polysaccharide transport in V. cholerae.  The 
capsule repeating subunit in NRT36S is a complex heteropolymer with four sugars.  
Polysaccharides consisting of heteropolymers in other species have been associated with 
the wzx/wzy pathway while polysaccharides consisting of homopolymers use the wzm/wzt 
pathways.  The structure of NRT36S suggests it may depend on the wzx/wzy pathway.  
The presence of wza further suggests it is a group 1 type capsule.  On the other hand, wzm 
seems to be involved in the capsule exportation in NRT36S since mutation in this gene 
decreased the capsule amount.  Therefore, capsule in NRT36S may use an exportation 
pathway involving the combination of wzx/wzy and wzm/wzt pathways.  Wzm is 
conserved in O-antigen or capsule biogenesis region of all the V. cholerae examined so 
far, including O139, which has both a capsule and O-antigen.  The precise mechanism of 
understanding LPS/CPS exportation in V. cholerae NRT36S remains unclear.  
The pandemic V. cholerae serogroup O1 does not have a capsule while most the 
environmental strains have capsules.  O1 V. cholerae could have evolved from an 
acapsular ancestral strain; alternatively it could have evolved from an encapsulated strain, 
which later lost its capsule as it became a human pathogen.  The fact that serogroup O1 
has been abundant for centuries may suggest that a capsule is not beneficial for the spread 
of this pathogen via human host.  V. cholerae O139 emerged in 1992 and caused 
epidemic in Bangladesh, but subsided for more than a decade and then re-emerged 
around 2004 (7).  More recent isolates (2002) of O139 have less capsular material than 
the isolates from 1992-1993 (170).  This evidence supports the idea that a capsule is not 
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beneficial for human adapted strains.  Production of CPS requires energy; perhaps the 
acapsular variant could out-compete the encapsulated variants in human intestine because 
of reduced energy needs.  However, this hypothesis will need to be tested. 
In the natural environment, capsule may be more beneficial for the growth of V. 
cholerae.  The majority of non-O1 V. cholerae isolates are encapsulated.  Bacteria won’t 
waste that much energy if a capsule is not advantageous to their survival.   
The role of capsule in the natural aquatic environment needs more investigation.  
Capsule is a virulence factor for non-O1 V. cholerae infecting humans.  However, 
infection of humans by non-O1 V. cholerae is an occasional event.  Capsules may help 
bacteria attach to the surface of phytoplankton and zooplankton.  But V. cholerae also 
lives in free planktonic form.  Capsules retain a lot of water and prevent bacteria from 
desiccation.  It may be possible that capsules provide a microenvironment, which serves 
as an osmotic buffering system for the cell and help cells to maintain their structure and 
regular metabolism.  Capsules may also protect bacterial from bacteriophage infection or 
grazing by predators.  
Many questions remain to be answered in the genesis and regulation of 
polysaccharide genes in V. cholerae.  In both cases in which a capsule has been studied, i. 
e., O139 AND NRT36S, the CPS/O-antigen share the same biogenesis region.  But these 
studies should be extended to include other serogroups to confirm our conclusion.  Is 
there a generalized theme in the biogenesis of polysaccharide in V. cholerae, or do 
different mechanisms existing in this species, similar to E. coli?  These questions remain 
to be answered by extending the study to include more serogroups.   
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One interesting question that arose while I was studying the surface polysaccharide 
is the relationships and the interactions between different polysaccharide forms.  The 
interaction between capsule and exopolysaccharide is especially interesting because both 
of them are loose surface entities.  The capsule structures in V. cholerae O139 and 
NRT36S are different.  I anticipate there would be many capsule structures in V. 
cholerae, considering the nature of a capsule from the other species, and the mobility and 
diversity of capsule genes of V. cholerae.  On the other hand, the exopolysaccharide gene 
cluster shares high similarity between O1 and NRT36S, suggesting their structures may 
be very similar.  The exopolysaccharide expressed in the rugose phenotype and promotes 
biofilm formation.  Biofilm is a survival strategy when bacteria encounter stress 
conditions.  Between epidemic periods, O1 V. cholerae exists as either planktonic VBNC 
form or in biofilms.  I would like to propose that non-O1 V. cholerae switches between 
encapsulated form and rugose form, one as a planktonic life style, one as surface attached 
or biofilm life style.  In this hypothesis, capsule should not co-express with 
exopolysaccharide at the same time.  Under this assumption, bacteria will need a 
regulation system to control the different expression of these polysaccharides. 
The interesting finding of CPS/O-antigen biogenesis sharing the same gene cluster 
and even sharing some common genes also raised the question of regulation.  
Understanding of the regulatory mechanisms underlying polysaccharide biosynthesis will 
lead to better understanding of the general regulation of surface polysaccharide 
expression in V. cholerae.  Functional studies with microarrays could be conducted to 
understand the regulation system.  The CPS/O-antigen biogenesis was a complicated 
system in O31 and some genes appeared to be redundant.  My examination of NRT36S 
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and A5 differentiate, to a limited extent, the genes for CPS and genes for O-antigen.  But 
most genes remained to be clarified.  Specific gene knockouts can be conducted to 
resolve the gene functions. 
The importance and impact of surface polysaccharide diversity in V. cholerae has 
been underappreciated until this study.  As a result, the study of polysaccharide 
biogenesis in V. cholerae is far from comprehensive compared to E. coli.  My data 
suggests that surface polysaccharides, including exopolysaccharide, O-antigen and CPS 
are related to each other.  My study provides the first insight to a non O-antigen capsule 
in V. cholerae.  However, my study is limited to only one isolate and I can only speculate 
as to the general scheme of capsule biogenesis in this diverse species.  Capsule typing is 
well established in many bacteria, including E. coli, Streptococcus pneumoniae and 
Neisseria meningitidis.  In contrast, capsule typing has not been applied to V. cholerae.  
Currently, we do not have complete knowledge of the capsule diversity in this species.  
Our preliminary data open many doors to future research, which will ultimately lead us to 
understanding the function, biogenesis regulation of capsule in V. cholerae, and how they 
related to the capsules in other species, and furthermore to understanding the function and 




1. Jiang, S. C., Louis, V., Choopun, N., Sharma, A., Huq, A. & Colwell, R. R. 
(2000) Appl Environ Microbiol 66, 140-7. 
2. Kaper, J., Lockman, H., Colwell, R. R. & Joseph, S. W. (1979) Appl Environ 
Microbiol 37, 91-103. 
3. Louis, V. R., Russek-Cohen, E., Choopun, N., Rivera, I. N., Gangle, B., Jiang, S. 
C., Rubin, A., Patz, J. A., Huq, A. & Colwell, R. R. (2003) Appl Environ 
Microbiol 69, 2773-85. 
4. Roszak, D. B. & Colwell, R. R. (1987) Microbiol Rev 51, 365-79. 
5. Glass, R. I., Becker, S., Huq, M. I., Stoll, B. J., Khan, M. U., Merson, M. H., Lee, 
J. V. & Black, R. E. (1982) Am J Epidemiol 116, 959-70. 
6. Huq, A., Colwell, R. R., Rahman, R., Ali, A., Chowdhury, M. A., Parveen, S., 
Sack, D. A. & Russek-Cohen, E. (1990) Appl Environ Microbiol 56, 2370-3. 
7. Alam, M., Sultana, M., Nair, G. B., Sack, R. B., Sack, D. A., Siddique, A. K., Ali, 
A., Huq, A. & Colwell, R. R. (2006) Appl Environ Microbiol 72, 2849-55. 
8. Colwell, R. R. & Huq, A. (1994) Vibrios in the environment: viable but non-
culturable Vibrio cholerae. (American Society for Microbiology, Washington, D. 
C.). 
9. Faruque, S. M., Biswas, K., Udden, S. M., Ahmad, Q. S., Sack, D. A., Nair, G. B. 
& Mekalanos, J. J. (2006) Proc Natl Acad Sci U S A 103, 6350-5. 
10. Huq, A., Small, E. B., West, P. A., Huq, M. I., Rahman, R. & Colwell, R. R. 
(1983) Appl Environ Microbiol 45, 275-83. 
11. Islam, M. S., Drasar, B. S. & Sack, R. B. (1994) J Diarrhoeal Dis Res 12, 87-96. 
 103
 
12. Tamplin, M. L., Gauzens, A. L., Huq, A., Sack, D. A. & Colwell, R. R. (1990) 
Appl Environ Microbiol 56, 1977-80. 
13. Matz, C., McDougald, D., Moreno, A. M., Yung, P. Y., Yildiz, F. H. & 
Kjelleberg, S. (2005) Proc Natl Acad Sci U S A 102, 16819-24. 
14. Yamai, S., Okitsu, T., Shimada, T. & Katsube, Y. (1997) Kansenshogaku Zasshi 
71, 1037-45. 
15. Bik, E. M., Bunschoten, A. E., Gouw, R. D. & Mooi, F. R. (1995) Embo J 14, 
209-16. 
16. Stroeher, U. H. & Manning, P. A. (1999) Genetics of Vibrio cholerae O1 and 
O139 surface polysaccharides (CRC Press, Boca Raton, Fl.). 
17. Johnson, J. A., Salles, C. A., Panigrahi, P., Albert, M. J., Wright, A. C., Johnson, 
R. J. & Morris, J. G., Jr. (1994) Infect Immun 62, 2108-10. 
18. Li, M., Shimada, T., Morris, J. G., Jr., Sulakvelidze, A. & Sozhamannan, S. 
(2002) Infect Immun 70, 2441-53. 
19. Kaper, J. B., Morris, J. G., Jr. & Levine, M. M. (1995) Clin Microbiol Rev 8, 48-
86. 
20. Heidelberg, J. F., Eisen, J. A., Nelson, W. C., Clayton, R. A., Gwinn, M. L., 
Dodson, R. J., Haft, D. H., Hickey, E. K., Peterson, J. D., Umayam, L., Gill, S. R., 
Nelson, K. E., Read, T. D., Tettelin, H., Richardson, D., Ermolaeva, M. D., 
Vamathevan, J., Bass, S., Qin, H., Dragoi, I., Sellers, P., McDonald, L., 
Utterback, T., Fleishmann, R. D., Nierman, W. C., White, O., Salzberg, S. L., 
Smith, H. O., Colwell, R. R., Mekalanos, J. J., Venter, J. C. & Fraser, C. M. 
(2000) Nature 406, 477-83. 
 104
 
21. Chen, C. Y., Wu, K. M., Chang, Y. C., Chang, C. H., Tsai, H. C., Liao, T. L., Liu, 
Y. M., Chen, H. J., Shen, A. B., Li, J. C., Su, T. L., Shao, C. P., Lee, C. T., Hor, 
L. I. & Tsai, S. F. (2003) Genome Res 13, 2577-87. 
22. Makino, K., Oshima, K., Kurokawa, K., Yokoyama, K., Uda, T., Tagomori, K., 
Iijima, Y., Najima, M., Nakano, M., Yamashita, A., Kubota, Y., Kimura, S., 
Yasunaga, T., Honda, T., Shinagawa, H., Hattori, M. & Iida, T. (2003) Lancet 
361, 743-9. 
23. Beltran, P., Delgado, G., Navarro, A., Trujillo, F., Selander, R. K. & Cravioto, A. 
(1999) J Clin Microbiol 37, 581-90. 
24. Byun, R., Elbourne, L. D., Lan, R. & Reeves, P. R. (1999) Infect Immun 67, 1116-
24. 
25. Garg, P., Aydanian, A., Smith, D., J. Glenn M, J., Nair, G. B. & Stine, O. C. 
(2003) Emerg Infect Dis 9, 810-4. 
26. Popovic, T., Bopp, C., Olsvik, O. & Wachsmuth, K. (1993) J Clin Microbiol 31, 
2474-82. 
27. Stroeher, U. H., Parasivam, G., Dredge, B. K. & Manning, P. A. (1997) J 
Bacteriol 179, 2740-7. 
28. Karaolis, D. K., Lan, R. & Reeves, P. R. (1995) J Bacteriol 177, 3191-8. 
29. Farfan, M., Minana-Galbis, D., Fuste, M. C. & Loren, J. G. (2002) J Bacteriol 
184, 1304-13. 
30. Karaolis, D. K., Johnson, J. A., Bailey, C. C., Boedeker, E. C., Kaper, J. B. & 
Reeves, P. R. (1998) Proc Natl Acad Sci U S A 95, 3134-9. 
 105
 
31. Karaolis, D. K., Lan, R., Kaper, J. B. & Reeves, P. R. (2001) Infect Immun 69, 
1947-52. 
32. Waldor, M. K. & Mekalanos, J. J. (1996) Science 272, 1910-4. 
33. Herrington, D. A., Hall, R. H., Losonsky, G., Mekalanos, J. J., Taylor, R. K. & 
Levine, M. M. (1988) J Exp Med 168, 1487-92. 
34. Taylor, R. K., Miller, V. L., Furlong, D. B. & Mekalanos, J. J. (1987) Proc Natl 
Acad Sci U S A 84, 2833-7. 
35. Gill, D. M. (1976) Biochemistry 15, 1242-8. 
36. Lonnroth, I. & Holmgren, J. (1973) J Gen Microbiol 76, 417-27. 
37. Holmgren, J., Lonnroth, I. & Svennerholm, L. (1973) Scand J Infect Dis 5, 77-8. 
38. Holmgren, J. & Svennerholm, A. M. (1977) J Infect Dis 136 Suppl, S105-12. 
39. Van Heyningen, W. E., Carpenter, C. C., Pierce, N. F. & Greenough, W. B., 3rd 
(1971) J Infect Dis 124, 415-8. 
40. O'Shea, Y. A., Reen, F. J., Quirke, A. M. & Boyd, E. F. (2004) J Clin Microbiol 
42, 4657-71. 
41. Morris, J. G., Jr., Takeda, T., Tall, B. D., Losonsky, G. A., Bhattacharya, S. K., 
Forrest, B. D., Kay, B. A. & Nishibuchi, M. (1990) J Clin Invest 85, 697-705. 
42. Chitnis, D. S., Sharma, K. D. & Kamat, R. S. (1982) J Med Microbiol 15, 53-61. 
43. Freter, R. & Jones, G. W. (1976) Infect Immun 14, 246-56. 
44. Cash, R. A., Music, S. I., Libonati, J. P., Snyder, M. J., Wenzel, R. P. & Hornick, 
R. B. (1974) J Infect Dis 129, 45-52. 
 106
 
45. Levine, M. M., Nalin, D. R., Craig, J. P., Hoover, D., Bergquist, E. J., Waterman, 
D., Holley, H. P., Hornick, R. B., Pierce, N. P. & Libonati, J. P. (1979) Trans R 
Soc Trop Med Hyg 73, 3-9. 
46. Aydanian, A. (2004)  (Univerisity of Maryland, Baltimore, Baltimore), Vol. 
Doctor of Philosophy. 
47. Comstock, L. E., Johnson, J. A., Michalski, J. M., Morris, J. G., Jr. & Kaper, J. B. 
(1996) Mol Microbiol 19, 815-26. 
48. Manning, P. A., Heuzenroeder, M. W., Yeadon, J., Leavesley, D. I., Reeves, P. R. 
& Rowley, D. (1986) Infect Immun 53, 272-7. 
49. Yamasaki, S., Shimizu, T., Hoshino, K., Ho, S. T., Shimada, T., Nair, G. B. & 
Takeda, Y. (1999) Gene 237, 321-32. 
50. Johnson, J. A., Panigrahi, P. & Morris, J. G., Jr. (1992) Infect Immun 60, 864-9. 
51. Griffith, F. (1928) Journal of Hygine 27, 113-159. 
52. Powell, J. L. (1999) Clin Lab Med 19, 537-52, vi. 
53. Strom, M. S. & Paranjpye, R. N. (2000) Microbes Infect 2, 177-88. 
54. Wright, A. C., Simpson, L. M., Oliver, J. D. & Morris, J. G., Jr. (1990) Infect 
Immun 58, 1769-73. 
55. Yoshida, S., Ogawa, M. & Mizuguchi, Y. (1985) Infect Immun 47, 446-51. 
56. Jesudason, M. V., Cherian, A. M. & John, T. J. (1993) Lancet 342, 431. 
57. Whitfield, C. (2006) Annu Rev Biochem 75, 39-68. 
58. MacLachlan, P. R., Keenleyside, W. J., Dodgson, C. & Whitfield, C. (1993) J 
Bacteriol 175, 7515-22. 
59. Orskov, I., Orskov, F., Jann, B. & Jann, K. (1977) Bacteriol Rev 41, 667-710. 
 107
 
60. Barrett, B., Ebah, L. & Roberts, I. S. (2002) Curr Top Microbiol Immunol 264, 
137-55. 
61. Cieslewicz, M. & Vimr, E. (1996) J Bacteriol 178, 3212-20. 
62. Simpson, D. A., Hammarton, T. C. & Roberts, I. S. (1996) J Bacteriol 178, 6466-
74. 
63. Whitfield, C. & Paiment, A. (2003) Carbohydr Res 338, 2491-502. 
64. Whitfield, C. & Roberts, I. S. (1999) Mol Microbiol 31, 1307-19. 
65. Henrichsen, J. (1995) J Clin Microbiol 33, 2759-62. 
66. Llull, D., Lopez, R. & Garcia, E. (2001) Curr Mol Med 1, 475-91. 
67. Bentley, S. D., Aanensen, D. M., Mavroidi, A., Saunders, D., Rabbinowitsch, E., 
Collins, M., Donohoe, K., Harris, D., Murphy, L., Quail, M. A., Samuel, G., 
Skovsted, I. C., Kaltoft, M. S., Barrell, B., Reeves, P. R., Parkhill, J. & Spratt, B. 
G. (2006) PLoS Genet 2, e31. 
68. White, P. B. (1938) J. Pathol. Bacteriol 46, 1-6. 
69. Frosch, M., Weisgerber, C. & Meyer, T. F. (1989) Proc Natl Acad Sci U S A 86, 
1669-73. 
70. Roberts, I. S. (1996) Annu Rev Microbiol 50, 285-315. 
71. Wright, A. C., Powell, J. L., Kaper, J. B. & Morris, J. G., Jr. (2001) Infect Immun 
69, 6893-901. 
72. Smith, A. B. & Siebeling, R. J. (2003) Infect Immun 71, 1091-7. 
73. Johnson, J. A., Joseph, A., Panigrahi, P. & Morris, J. G. (1992) in American 
society for microbiology annual meeting, New Orleans, Louisiana). 
 108
 
74. Waldor, M. K., Colwell, R. & Mekalanos, J. J. (1994) Proc Natl Acad Sci U S A 
91, 11388-92. 
75. Preston, L. M., Xu, Q., Johnson, J. A., Joseph, A., Maneval, D. R., Jr., Husain, K., 
Reddy, G. P., Bush, C. A. & Morris, J. G., Jr. (1995) J Bacteriol 177, 835-8. 
76. Cox, A. D., Brisson, J. R., Varma, V. & Perry, M. B. (1996) Carbohydr Res 290, 
43-58. 
77. Yildiz, F. H., Liu, X. S., Heydorn, A. & Schoolnik, G. K. (2004) Mol Microbiol 
53, 497-515. 
78. Yildiz, F. H. & Schoolnik, G. K. (1999) Proc Natl Acad Sci U S A 96, 4028-33. 
79. Ali, A., Mahmud, Z. H., Morris, J. G., Jr., Sozhamannan, S. & Johnson, J. A. 
(2000) Infect Immun 68, 6857-64. 
80. McCarter, L. L. (1998) J Bacteriol 180, 3166-73. 
81. Guvener, Z. T. & McCarter, L. L. (2003) J Bacteriol 185, 5431-41. 
82. Hammerschmidt, S., Hilse, R., van Putten, J. P., Gerardy-Schahn, R., Unkmeir, A. 
& Frosch, M. (1996) Embo J 15, 192-8. 
83. Hammerschmidt, S., Muller, A., Sillmann, H., Muhlenhoff, M., Borrow, R., Fox, 
A., van Putten, J., Zollinger, W. D., Gerardy-Schahn, R. & Frosch, M. (1996) Mol 
Microbiol 20, 1211-20. 
84. Waite, R. D., Struthers, J. K. & Dowson, C. G. (2001) Mol Microbiol 42, 1223-
32. 
85. Linton, D., Gilbert, M., Hitchen, P. G., Dell, A., Morris, H. R., Wakarchuk, W. 
W., Gregson, N. A. & Wren, B. W. (2000) Mol Microbiol 37, 501-14. 
 109
 
86. Abraham, J. M., Freitag, C. S., Clements, J. R. & Eisenstein, B. I. (1985) Proc 
Natl Acad Sci U S A 82, 5724-7. 
87. Low, D., Braaten, B. A. & Vvan der Woude, M. (1996) Fimbriae (ASM press, 
Washington, D. C.). 
88. Fussenegger, M., Rudel, T., Barten, R., Ryll, R. & Meyer, T. F. (1997) Gene 192, 
125-34. 
89. Karlyshev, A. V., Linton, D., Gregson, N. A. & Wren, B. W. (2002) Microbiology 
148, 473-80. 
90. Ottemann, K. M. & Lowenthal, A. C. (2002) Infect Immun 70, 1984-90. 
91. Dempsey, J. A., Litaker, W., Madhure, A., Snodgrass, T. L. & Cannon, J. G. 
(1991) J Bacteriol 173, 5476-86. 
92. Stern, A. & Meyer, T. F. (1987) Mol Microbiol 1, 5-12. 
93. Dworkin, J. & Blaser, M. J. (1997) Mol Microbiol 26, 433-40. 
94. van Ham, S. M., van Alphen, L., Mooi, F. R. & van Putten, J. P. (1993) Cell 73, 
1187-96. 
95. de Vries, N., Duinsbergen, D., Kuipers, E. J., Pot, R. G., Wiesenekker, P., Penn, 
C. W., van Vliet, A. H., Vandenbroucke-Grauls, C. M. & Kusters, J. G. (2002) J 
Bacteriol 184, 6615-23. 
96. Banerjee, A., Wang, R., Supernavage, S. L., Ghosh, S. K., Parker, J., Ganesh, N. 
F., Wang, P. G., Gulati, S. & Rice, P. A. (2002) J Exp Med 196, 147-62. 
97. van der Ende, A., Hopman, C. T. & Dankert, J. (2000) Infect Immun 68, 6685-90. 
98. Willems, R., Paul, A., van der Heide, H. G., ter Avest, A. R. & Mooi, F. R. (1990) 
Embo J 9, 2803-9. 
 110
 
99. Hagblom, P., Segal, E., Billyard, E. & So, M. (1985) Nature 315, 156-8. 
100. van der Woude, M. W. & Baumler, A. J. (2004) Clin Microbiol Rev 17, 581-611, 
table of contents. 
101. Klemm, K. W. (1986) Clin Orthop Relat Res, 174-81. 
102. Braaten, B. A., Nou, X., Kaltenbach, L. S. & Low, D. A. (1994) Cell 76, 577-88. 
103. Nicholson, B. & Low, D. (2000) Mol Microbiol 35, 728-42. 
104. Kotetishvili, M., Stine, O. C., Chen, Y., Kreger, A., Sulakvelidze, A., 
Sozhamannan, S. & Morris, J. G., Jr. (2003) J Clin Microbiol 41, 2191-6. 
105. Chowdhury, N. R., Stine, O. C., Morris, J. G. & Nair, G. B. (2004) J Clin 
Microbiol 42, 1280-2. 
106. Li, M., Kotetishvili, M., Chen, Y. & Sozhamannan, S. (2003) Appl Environ 
Microbiol 69, 1728-38. 
107. Bhaskaran, K. (1959) Indian J Med Res 47, 253-60. 
108. Hedges, R. W., Vialard, J. L., Pearson, N. J. & O'Grady, F. (1977) Antimicrob 
Agents Chemother 11, 585-8. 
109. Prescott, L. M., Datta, A. & Datta, G. C. (1968) Bull World Health Organ 39, 
971-3. 
110. Redfield, R. J. (2001) Nat Rev Genet 2, 634-9. 
111. Meibom, K. L., Blokesch, M., Dolganov, N. A., Wu, C. Y. & Schoolnik, G. K. 
(2005) Science 310, 1824-7. 
112. Stahl, F. W., Crasemann, J. M. & Stahl, M. M. (1975) J Mol Biol 94, 203-12. 




114. Redfield, R. J., Findlay, W. A., Bosse, J., Kroll, J. S., Cameron, A. D. & Nash, J. 
H. (2006) BMC Evol Biol 6, 82. 
115. Sourice, S., Biaudet, V., El Karoui, M., Ehrlich, S. D. & Gruss, A. (1998) Mol 
Microbiol 27, 1021-9. 
116. Bakkali, M., Chen, T. Y., Lee, H. C. & Redfield, R. J. (2004) Proc Natl Acad Sci 
U S A 101, 4513-8. 
117. Goodman, S. D. & Scocca, J. J. (1988) Proc Natl Acad Sci U S A 85, 6982-6. 
118. Smith, H. O., Gwinn, M. L. & Salzberg, S. L. (1999) Res Microbiol 150, 603-16. 
119. Stokes, H. W. & Hall, R. M. (1989) Mol Microbiol 3, 1669-83. 
120. Mazel, D. (2006) Nat Rev Microbiol 4, 608-20. 
121. Hochhut, B., Lotfi, Y., Mazel, D., Faruque, S. M., Woodgate, R. & Waldor, M. K. 
(2001) Antimicrob Agents Chemother 45, 2991-3000. 
122. Mazel, D., Dychinco, B., Webb, V. A. & Davies, J. (1998) Science 280, 605-8. 
123. Rowe-Magnus, D. A., Guerout, A. M. & Mazel, D. (2002) Mol Microbiol 43, 
1657-69. 
124. Sozhamannan, S., Deng, Y. K., Li, M., Sulakvelidze, A., Kaper, J. B., Johnson, J. 
A., Nair, G. B. & Morris, J. G., Jr. (1999) Infect Immun 67, 5033-40. 
125. Johnson, J. A., Joseeph, A., Panigrahi, P. & Morris, J. G. (1992) in American 
society for microbiology annual meeting, New Orleans, Louisiana). 
126. Cox, A. D. & Perry, M. B. (1996) Carbohydr Res 290, 59-65. 
127. Knirel, Y. A., Widmalm, G., Senchenkova, S. N., Jansson, P. E. & Weintraub, A. 
(1997) Eur J Biochem 247, 402-10. 
 112
 
128. Simpson, L. M., White, V. K., Zane, S. F. & Oliver, J. D. (1987) Infect Immun 55, 
269-72. 
129. Chatzidaki-Livanis, M., Jones, M. K. & Wright, A. C. (2006) J Bacteriol 188, 
1987-98. 
130. Bergstrom, N., Nair, G. B., Weintraub, A. & Jansson, P. E. (2002) Carbohydr Res 
337, 813-7. 
131. Panigrahi, P. & J.G., M. (1993) in 93rd General Meeting, American Society for 
Microbiology, Atlanta, Georgia). 
132. Hobbs, M. & Reeves, P. R. (1994) Mol Microbiol 12, 855-6. 
133. Li, Q., Hobbs, M. & Reeves, P. R. (2003) Microbiology 149, 2463-74. 
134. Cserzo, M., Bernassau, J. M., Simon, I. & Maigret, B. (1994) J Mol Biol 243, 
388-96. 
135. Reid, A. N. & Whitfield, C. (2005) J Bacteriol 187, 5470-81. 
136. Feng, L., Senchenkova, S. N., Yang, J., Shashkov, A. S., Tao, J., Guo, H., Cheng, 
J., Ren, Y., Knirel, Y. A., Reeves, P. R. & Wang, L. (2004) J Bacteriol 186, 
4510-9. 
137. Dolan-Livengood, J. M., Miller, Y. K., Martin, L. E., Urwin, R. & Stephens, D. S. 
(2003) J Infect Dis 187, 1616-28. 
138. Hammerschmidt, S., Birkholz, C., Zahringer, U., Robertson, B. D., van Putten, J., 
Ebeling, O. & Frosch, M. (1994) Mol Microbiol 11, 885-96. 




140. Kroll, J. S., Zamze, S., Loynds, B. & Moxon, E. R. (1989) J Bacteriol 171, 3343-
7. 
141. Swartley, J. S., Ahn, J. H., Liu, L. J., Kahler, C. M. & Stephens, D. S. (1996) J 
Bacteriol 178, 4052-9. 
142. Kondo, S. & Hisatsune, K. (1989) Microbiol Immunol 33, 641-8. 
143. Reeves, P. P. & Wang, L. (2002) Curr Top Microbiol Immunol 264, 109-35. 
144. Arita, M., Takeda, T., Honda, T. & Miwatani, T. (1986) Infect Immun 52, 45-9. 
145. de Lorenzo, V., Herrero, M., Jakubzik, U. & Timmis, K. N. (1990) J Bacteriol 
172, 6568-72. 
146. Herrero, M., de Lorenzo, V. & Timmis, K. N. (1990) J Bacteriol 172, 6557-67. 
147. Martin, V. J. & Mohn, W. W. (1999) J Microbiol Methods 35, 163-6. 
148. Ewing, B. & Green, P. (1998) Genome Res 8, 186-94. 
149. Ewing, B., Hillier, L., Wendl, M. C. & Green, P. (1998) Genome Res 8, 175-85. 
150. Gordon, D. (2004) Viewing and Editing Assembled Sequences Using Consed 
(John Wilery & Co.,, New York). 
151. Margulies, M., Egholm, M., Altman, W. E., Attiya, S., Bader, J. S., Bemben, L. 
A., Berka, J., Braverman, M. S., Chen, Y. J., Chen, Z., Dewell, S. B., Du, L., 
Fierro, J. M., Gomes, X. V., Godwin, B. C., He, W., Helgesen, S., Ho, C. H., 
Irzyk, G. P., Jando, S. C., Alenquer, M. L., Jarvie, T. P., Jirage, K. B., Kim, J. B., 
Knight, J. R., Lanza, J. R., Leamon, J. H., Lefkowitz, S. M., Lei, M., Li, J., 
Lohman, K. L., Lu, H., Makhijani, V. B., McDade, K. E., McKenna, M. P., 
Myers, E. W., Nickerson, E., Nobile, J. R., Plant, R., Puc, B. P., Ronan, M. T., 
Roth, G. T., Sarkis, G. J., Simons, J. F., Simpson, J. W., Srinivasan, M., Tartaro, 
 114
 
K. R., Tomasz, A., Vogt, K. A., Volkmer, G. A., Wang, S. H., Wang, Y., Weiner, 
M. P., Yu, P., Begley, R. F. & Rothberg, J. M. (2005) Nature 437, 376-80. 
152. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) J Mol 
Biol 215, 403-10. 
153. Salzberg, S. L., Delcher, A. L., Kasif, S. & White, O. (1998) Nucleic Acids Res 
26, 544-8. 
154. Rutherford, K., Parkhill, J., Crook, J., Horsnell, T., Rice, P., Rajandream, M. A. & 
Barrell, B. (2000) Bioinformatics 16, 944-5. 
155. Stine, O. C., Sozhamannan, S., Gou, Q., Zheng, S., Morris, J. G., Jr. & Johnson, J. 
A. (2000) Infect Immun 68, 7180-5. 
156. Kurtz, S., Phillippy, A., Delcher, A. L., Smoot, M., Shumway, M., Antonescu, C. 
& Salzberg, S. L. (2004) Genome Biol 5, R12. 
157. Jermyn, W. S. & Boyd, E. F. (2002) Microbiology 148, 3681-93. 
158. Galen, J. E., Ketley, J. M., Fasano, A., Richardson, S. H., Wasserman, S. S. & 
Kaper, J. B. (1992) Infect Immun 60, 406-15. 
159. Ogawa, A., Kato, J., Watanabe, H., Nair, B. G. & Takeda, T. (1990) Infect Immun 
58, 3325-9. 
160. Boyd, D., Peters, G. A., Cloeckaert, A., Boumedine, K. S., Chaslus-Dancla, E., 
Imberechts, H. & Mulvey, M. R. (2001) J Bacteriol 183, 5725-32. 
161. Jonson, G., Holmgren, J. & Svennerholm, A. M. (1991) Microb Pathog 11, 433-
41. 
162. Fullner, K. J. & Mekalanos, J. J. (1999) Infect Immun 67, 1393-404. 
 115
 
163. Dziejman, M., Serruto, D., Tam, V. C., Sturtevant, D., Diraphat, P., Faruque, S. 
M., Rahman, M. H., Heidelberg, J. F., Decker, J., Li, L., Montgomery, K. T., 
Grills, G., Kucherlapati, R. & Mekalanos, J. J. (2005) Proc Natl Acad Sci U S A 
102, 3465-70. 
164. Project, N. M. G. A. (2005)  (National Center for Biotechnology Information, 
NIH, Bethesda, MD 20894, USA. 
165. Krause, L., McHardy, A. C., Puhler, A., Stoye, J. & Meyer, F. (2006) Nucleic 
Acids Research. 
166. Chen, Y., Bystricky, P., Adeyeye, J., Panigrahi, P., Ali, A., Johnson, J. A., Bush, 
C. A., Morris, J. G. & Stine, O. C. (2006). 
167. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W. & 
Lipman, D. J. (1997) Nucleic Acids Res 25, 3389-402. 
168. Chenna, R., Sugawara, H., Koike, T., Lopez, R., Gibson, T. J., Higgins, D. G. & 
Thompson, J. D. (2003) Nucleic Acids Res 31, 3497-500. 
169. Page, R. D. (1996) Comput Appl Biosci 12, 357-8. 
170. Qadri, F., Svennerholm, A. M., Shamsuzzaman, S., Bhuiyan, T. R., Harris, J. B., 
Ghosh, A. N., Nair, G. B., Weintraub, A., Faruque, S. M., Ryan, E. T., Sack, D. 




Name:   Yuansha Chen 
Address: 3426 Orange Grove Ct. 
  Ellicott City, MD 21043 USA 
Phone:  (410) 480-0138 (home), (410) 706-1609 (lab) 
e-mail:  ychen@epi.umaryland.edu 
Education: 
Doctor of Philosophy  2003-2006 
    Marine, Estuarine and Environmental Science 
Area of specialization: Environmental Molecular 
Biology/Biotechnology 
University of Maryland 
College Park, Maryland 
Graduate Student  2001-2003 
University of Maryland 
Master of Science  1995–1998 
Department of Biochemistry and Molecular Biology 
Oklahoma State University 
Stillwater, Oklahoma 74075-3035 
Bachelor of Science  1989-1993 
Department of Biochemistry 
School of Life Sciences 
Zhongshan University (Sun Yat-Sen University) 
 
 
Guangzhou, P. R. China 510275 
Work Experiences: 
Senior Research Assistant  2003-present 
Department of Epidemiology and Preventive Medicine 
University of Maryland, Baltimore 
Senior Research Assistant 2000-2003 
Genomic Core Facility, School of Medicine 
University of Maryland, Baltimore 
Senior Research Assistant 1998–2000 
Center of Genetics for Asthma and Complex Diseases 
School of Medicine 
University of Maryland, Baltimore 
Research Assistant  1995-1998 
Department of Biochemistry and Molecular Biology 
Oklahoma State University 
Research Assistant  1993-1995 
Zhuxin Biotech and Pharmaceutical Company 
Zhuhai City, China 
 
 
Publications and manuscripts: 
Chen, Y., Bystricky, P., Adeyeye, J., Panigrahi, P., Ali, A., Johnson, J.A., Bush, C.A., 
Morris, J.G., & Stine, O.C. (submitted 2006). 
Chen, Y., Johnson, J.A., Pusch, D.G., Morris, J.G., & Stine, O.C. (submitted 2006). 
Chen, Y., Stine, O.C., Morris, J.G., & Johnson, J.A. (in preparation 2006). 
Kotetishvili, M., Stine, O.C., Chen, Y., Kreger, A., Sulakvelidze, A., Sozhamannan, S., & 
Morris, J.G., Jr. (2003) J Clin Microbiol 41: 2191-2196. 
Li, M., Kotetishvili, M., Chen, Y., & Sozhamannan, S. (2003) Appl Environ Microbiol 
69: 1728-1738. 
Davis, E.M., Chen, Y., Essenberg, M., & Pierce, M.L. (1998) Plant Physiol. 116: 1192. 
Abstracts:
Chen, Y., Bystricky, P., Adeyeye, J., Panigrahi, P., Ali, A., Johnson, J.A., Bush, C.A., 
Morris, J.G., & Stine, O.C.  (2006).  in FASEB summer research conferences: 
microbial polysaccharides of medical, agricultural, and industrial importance. 
Tucson, Arizona). 
Stine, O.C., Kotetishvili, M., Chen, Y., Snyder, A., Turabelidze, D., Scott, J., Gombas, 
D.,. Morris, J. G, & Sulakvelidze, A. (2001) in 101st American society for 
microbiology general meeting, Orlando, Florida). 
Li, M, Chen, Y, Shimada, T, Johnson, J.A., Morris, J.G., Stine, O.C., & Sozhamannan, S 
(2001) in 101st American society for microbiology general meeting, Orlando, 
Florida). 
 
